

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Predicting postoperative fatigue in surgically treated lung cancer patients – a longitudinal five-month follow-up study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028192
Article Type:	Research
Date Submitted by the Author:	26-Nov-2018
Complete List of Authors:	Hugoy, Therese ; University of Oslo, Institute of Health and Society, Faculty of Medicine, ; Lovisenberg Diakonale Hogskole Lerdal, Anners; University of Oslo, Dept. of Nursing Science; Lovisenberg Diakonale Hospital, Dept. of Research Rustoen, Tone; University of Oslo, Norway, Institute of Health and Society, Faculty of Medicine; Oslo universitetssykehus Ulleval, Department of Research and Development, Division of Emergencies and Critical Care Oksholm, Trine; VID Vitenskapelige Hogskole, Faculty of Health Studies, Campus Haraldsplass
Keywords:	Fatigue, Lung Cancer, Neoplasm, Quality of Life, SURGERY

SCHOLARONE™
Manuscripts

1
2
3 **Predicting postoperative fatigue in surgically treated lung cancer patients – a**
4 **longitudinal five-month follow-up study.**
5
6

7 Therese Hugøy^{a,b,c}, Anners Lerdal^{a,d} Tone Rustøen^{a,e}, Trine Oksholm^f
8
9

10
11 ^aDepartment of Nursing Science, Institute of Health and Society, Faculty of Medicine,
12 University of Oslo, Norway.
13

14 ^bCentre for Patient centered heart- and lung research. Department of cardiothoracic surgery.
15 Division of Cardiovascular and Pulmonary Diseases. Oslo University Hospital, Oslo, Norway.
16 (T.H.)
17

18
19 ^cLovisenberg Diaconal University College, Lovisenberggt. 15B, 0456 Oslo
20

21 ^dDepartment for Patient Safety and Research, Lovisenberg Diaconal Hospital, P.O. Box 4970
22 Nydalen, 0440 Oslo, Norway
23

24
25 ^e Department of Research and Development, Division of Emergencies and Critical Care, Oslo
26 University Hospital, P.O. Box 4956 Nydalen, 0424 Oslo, Norway;
27

28 ^f VID Specialized University, Faculty of Health Studies, Campus Haraldsplass, P.O. Box 184
29 Vinderen, 0319 Oslo, Norway
30
31

32
33
34 *Corresponding author at:
35 Trine Oksholm
36 trine.oksholm@vid.no
37
38

39
40
41
42 Word count: 3026
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Despite the negative influence of fatigue on quality of life in patients who undergo lung cancer surgery, little is known about the possible predictors of postoperative fatigue. The aim of this study was to examine demographic and clinical characteristics that might predict postoperative fatigue five months after lung cancer surgery.

Design: A prospective longitudinal follow up study comprising pre- and postoperative questionnaires, including Lee Fatigue Scale, and sociodemographic and clinical data.

Setting: Three university hospitals in Norway (e.g., Oslo University Hospital, St. Olav University Hospital, Haukeland University Hospital).

Participants: In total, 196 surgically treated patients who answered the questionnaires both preoperatively and at five-month follow-up with valid fatigue scores.

Results: Bivariate analyses showed that preoperative fatigue was associated with comorbidities and the symptoms of shortness of breath, cough, depression, anxiety, sleep disturbance, and pain. Only cough was directly associated with preoperative fatigue in a regression model. Comorbidities and the symptoms of shortness of breath, cough, depression, and sleep disturbance were associated with postoperative fatigue in the bivariate analyses, but only shortness of breath was associated with postoperative fatigue in the regression model. We did not find any significant correlations between fatigue and any treatment variable.

Conclusion: Clinicians should pay special attention to lung symptoms and be aware that these may lead to long-term postoperative fatigue. Further research should examine whether interventions reducing lung symptoms, such as shortness of breath and coughing, may prevent development of fatigue in patients undergoing lung cancer surgery.

Key words: Fatigue, Lung Cancer, Neoplasm, Quality of Life, Surgery

Strengths and limitations of this study

- A rather large sample of surgically treated lung cancer patients were included in the study
- Patients' fatigue was measured both preoperatively and after surgery
- Several clinical, treatment and medical variables as well as symptoms that might be related to fatigue was assessed
- There was a five-month gap between the two measurement points. During this time, other factors might have influenced patients' fatigue experience.
- There were limited information on symptom management interventions such as physiotherapy and rehabilitation

1. Introduction

Lung cancer (LC) is presently one of the most common malignancies, and it is estimated that 20% of cancer-related deaths are caused by LC,[1]. Only 20% of patients diagnosed with non-small-cell lung cancer meet the criteria for surgery due to their late stage at diagnosis; for these patients, surgery may be curative,[2]. In Norway during 2014, five-year LC survival was generally 19% in women and 13% in men,[1]. In surgically treated patients, the five-year survival ranges from 50% to 70%, depending on the tumor stage at surgery.

Fatigue is common among cancer patients. An estimated 75–90% of LC patients report fatigue after cancer treatment,[3,4]. Fatigue has been described as a complex, multidimensional symptom and has been defined as a sense of exhaustion, lack of energy, or tiredness distinct from sleepiness, sadness, or weakness,[5]. Cancer-related fatigue is related to cancer or its treatment, and interferes with usual functioning,[3]. Fatigue has a negative impact on patients' health-related quality of life (HRQOL),[6], their ability to receive treatment, and their long-term prognosis. Although there are limited data on LC and fatigue in patients who have undergone surgery, it has been shown that fatigue has a negative impact on

1
2
3 HRQOL in LC survivors,[7]. One study showed that fatigue was a significant predictor of
4 survival at each time point assessed,[8]. In another study on symptom severity after
5 thoracotomy, fatigue was reported as the most common and severe symptom at every time
6 point,[7].
7
8
9
10
11

12 Several studies have reported interrelations between fatigue, cough, and dyspnea,[8–
13 11]. Fatigue is also strongly related to symptoms of depression and anxiety,[12,13].
14 Associations between fatigue and sex, pain, insomnia, and dyspnea have also been
15 reported,[12,14]. Studies on fatigue in populations with lung cancer in different stages have
16 also shown strong correlations between fatigue and sleep disturbance,[6,15–17]. Sarna et
17 al.,[12] found that symptom severity in surgical patients was related to the extent of their
18 comorbid condition. Other studies of LC patients have also shown correlations between
19 comorbidities and fatigue,[6], as well as strong correlations between pulmonary diseases such
20 as COPD and asthma, and fatigue,[3,18]. Fatigue has a negative impact on both LC patients
21 and survivors in general,[19]; however, to our knowledge, there have been no studies to date
22 specifically investigating fatigue in surgically treated LC patients.
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Thus, our aim was to examine the relationships between fatigue and disease
38 characteristics, treatment, and other symptoms. We hypothesized that fatigue levels at five-
39 month follow-up would be significantly related to: (1) clinical variables (preoperative
40 comorbidities, forced expiratory volume in one second [FEV1], and forced vital capacity
41 [FVC]); (2) preoperative symptoms (shortness of breath, coughing, depression, anxiety, pain,
42 and sleep disturbance); and (3) treatment and medical variables (surgery type, cancer stage,
43 and adjuvant therapy).
44
45
46
47
48
49
50
51
52
53

54 **2. Material and methods**

55
56
57 This study is part of a larger, longitudinal investigation of symptoms in LC patients who
58 were eligible for surgery,[20–22] for which data were collected prior to surgery and
59
60

1
2
3 prospectively at four time points up to one year after surgery. Here, we analyzed the data
4
5 collected prior to surgery and at the five-month follow-up to gain insight into patients'
6
7 experiences with fatigue before surgery and after the immediate postoperative period.
8
9

10 11 *2.1. Patients and settings*

12
13
14 Patients were included if they were 18 years or older, scheduled for primary LC surgery,
15
16 and could understand, read, and write Norwegian. Patients with a benign or metastatic
17
18 disease, whose surgery was canceled, or who had cognitive impairment, were excluded. We
19
20 recruited patients from three university hospitals in Norway: Oslo University Hospital, St.
21
22 Olav University Hospital, and Haukeland University Hospital.
23
24

25 26 *2.2. Study procedures*

27
28
29 Hospital research staff approached patients and explained the study purpose: 91% of the
30
31 participants were recruited in the hospital 1–3 days before surgery, and the remainder in
32
33 outpatient clinics prior to surgery. The patients completed several self-report questionnaires
34
35 with information on sociodemographic and clinical characteristics, and symptoms both prior
36
37 to surgery and at a five-month follow-up. Data on type of tumor, cancer stage, surgery type,
38
39 and lung function were collected from the patients' medical records. FEV1 and FVC were
40
41 measured preoperatively using a spirometer. Five months after surgery, patients received
42
43 questionnaires by regular mail, along with a postage-paid return envelope.
44
45
46
47

48 49 *2.3. Instruments and assessment*

50 51 *2.3.1. Sociodemographic, clinical, symptom, and fatigue characteristics*

52
53
54 Patients provided information on their sex, marital status, living situation, level of
55
56 education, and employment status. Information on age, smoking status, FEV1, tumor
57
58 histology, cancer stage, type of surgery, pre- and postoperative treatment, postoperative
59
60

1
2
3 complications, and TNM classification were collected from patients' medical records; the
4
5 TNM classification is a system for cancer staging based on tumor (T), node (N), and
6
7 metastasis (M).
8
9

10 2.3.2. Comorbidities

11
12 Comorbidities were measured using the Self-administered Comorbidity Questionnaire-
13
14 19 (SCQ-19),[23] on which scores can range from 0 to 57, with a higher score indicating a
15
16 more severe comorbidity profile. The SCQ includes 16 comorbidities and three optional
17
18 conditions. Patients indicated whether or not they had the comorbid condition (yes/no); if they
19
20 had the condition they were asked if they received treatment for it; and finally if it limited
21
22 their activities. The SCQ-19 has well-established validity and reliability and has been used to
23
24 assess comorbidity in Norwegian oncology patients,[23]. Only the number of comorbidities
25
26 was used in the present study.
27
28
29

30 2.3.3. Fatigue

31
32 The Lee Fatigue Scale (LFS),[5] was used to measure fatigue at baseline and five-month
33
34 follow-up. The LFS consists of 18 items designed to assess fatigue (13 items) and energy (5
35
36 items). We used only the 13 fatigue items in this study. Patients were asked to rate each item
37
38 on a 0–10 scale, with a higher score indicating greater fatigue severity. A fatigue score was
39
40 calculated using the mean of the 13 items at each measurement. The LFS has well-established
41
42 validity and reliability,[24,25]. Fatigue scores at baseline were defined as preoperative fatigue
43
44 and at five-month follow-up as postoperative fatigue.
45
46
47
48
49

50 2.3.4. Shortness of breath and cough

51
52 The European Organization for Research and Treatment of Cancer Quality-of-Life
53
54 Questionnaire – Lung Cancer Module (EORTC QLQ-LC13),[26] was used to measure
55
56 shortness of breath and cough. Patients were asked to rate their severity on each shortness of
57
58 breath and cough item using a four-point Likert scale where 1 = not at all; 2 = a little; 3 =
59
60

1
2
3 quite a bit; and 4 = very much. The EORTC QLQ-LC13 has been validated in Norwegian LC
4 patients,[27,28].
5
6

7 8 *2.3.5. Depression* 9

10 The Center for Epidemiologic Studies – Depression Scale (CES-D),[29] was used to
11 measure depression symptoms. The scale has 20 items related to depression and patients were
12 asked to report how they felt during the past week. Each item was rated on a four-point Likert
13 scale and scores ranged from 0 to 60, with a higher score indicating a higher level of
14 depression. A total depression score was calculated as the mean of all the sub scores.
15 Acceptable reliability and validity have been reported in a previous study,[30].
16
17
18
19
20
21
22
23
24

25 *2.3.6. Anxiety* 26

27 The State-Trait Anxiety Inventory (STAI, Y-2),[31] was used to measure anxiety. The
28 STAI includes 20 items related to anxiety rated on a four-point Likert scale. Scores range
29 from 20 to 80, with a higher score indicating a higher level of anxiety. The STAI has been
30 validated in LC patients,[32].
31
32
33
34
35
36

37 *2.3.7. Sleep disturbance* 38

39 The General Sleep Disturbance Scale (GSDS),[33] was used to measure sleep
40 disturbance. The GSDS consists of 21 items related to sleep disturbance. Each item is rated on
41 a numeric rating scale ranging from 0 (never) to 7 (every day). A sleep disturbance score was
42 calculated from the mean of all scale items. Higher scores indicate more severe sleep
43 disturbance. The GSDS has been validated in cancer patients,[24].
44
45
46
47
48
49
50

51 *2.3.8. Pain* 52

53 The Brief-Pain Inventory (BPI),[34] was used to measure pain interference. The BPI is
54 a multidimensional questionnaire measuring pain intensity (four items), pain interference
55 (seven items), pain relief (one item), and pain location (body map). Only pain interference
56 was used in the present study. The seven interference items (general activity, normal work,
57
58
59
60

1
2
3 walking ability, mood, relationships with other people, sleep, and enjoyment of life) were
4 combined into a single interference item. The measurement scale ranges from 0 to 10, with
5
6 higher scores indicating more pain interfering with daily living. The BPI has been validated in
7
8 Norwegian cancer patients,[35].
9
10
11

12 13 *2.4. Ethics*

14
15
16 The Regional Ethics Committee for the South-East 2010/1508, and the Institutional
17
18 Review Boards (Personvernombudet) at each hospital approved the study. Each participant
19
20 received written information about the study and signed informed consent.
21
22

23 24 *2.5. Statistical analyses*

25
26
27 Descriptive statistics were used to describe the sociodemographic, clinical, and
28
29 treatment characteristics of the patient sample. Differences between sexes were analyzed
30
31 using a chi-squared test for categorical variables and an independent Student's *t* test for the
32
33 continuous variables. One-way ANOVA was used to explore differences within groups on
34
35 levels of pre- and postoperative fatigue. Patients with more than 20% of missing items on the
36
37 LFS were excluded from analyses. The bivariate relationships between symptoms and fatigue
38
39 at baseline were assessed using Pearson correlation analyses. Variables with significant
40
41 correlation coefficients on bivariate analyses were included in a hierarchical linear analyses.
42
43
44

45
46 Two stepwise multivariate regression analyses were performed. In the first analysis,
47
48 preoperative fatigue was the dependent variable. In the second analysis, postoperative fatigue
49
50 was the dependent variable. In both analyses, age and sex were entered in step one. Clinical
51
52 variables including comorbidities, FEV1, and FVC were entered in step two. Finally, the
53
54 symptom variables of shortness of breath, cough, depression, anxiety, sleep disturbance, and
55
56 pain interference were entered in step three. For the second regression analysis, the model
57
58
59
60

Table 1

Demographic, clinical, and treatment characteristics of the patients (N=196).

	Total	Men	Women	Statistics	p-value
Sociodemographics					
Age in years (mean, SD)	196	66.7 (8.2)	64.1 (7.9)	t 2.28 (194)	0.024
		% (n)	% (n)	χ (df)	
Cohabitation (living with someone)	147	84.0 (89)	(69.0) 58	5.95 (1)	0.015

also included a fourth step in which preoperative fatigue was included as an independent variable.

The entry of variables in different model steps was carried out according to theoretical and logical considerations. For all analyses, $p < 0.05$ was considered statistically significant. Post hoc statistical power was calculated for hierarchical multiple regression: with an effect size (f^2) for set B (five-month follow-up) at 0.15 (medium), [36], 11 predictors in set A and 12 in set B, a probability level of 0.05, and a sample size of 196, the observed power for the addition of set B was 0.95, [37]. Data were analyzed using SPSS (IBM Corporation, Armonk, NY, USA) version 24.0.

3. Results

3.1. Sample characteristics

A total of 264 patients consented to participate in the study. Among these, 196 patients who answered the questionnaire both preoperatively and at five-month follow-up and had valid fatigue scores were included in the study. Sample characteristics are shown in Table 1. Most of the sample had adenocarcinoma stage 1A or 1B, received no preoperative treatment and had a lobectomy.

The mean preoperative fatigue scores were 2.49 (SD=2.02) for men and 2.47 (SD=1.96) for women. At the five-month follow-up, the postoperative fatigue scores were 3.0 (SD=2.1) for men and 2.9 (SD=2.1) for women. There were no significant differences in fatigue level preoperatively between those who completed or did not complete the postoperative fatigue scale.

1						
2						
3	Work status					
4	Full or part time	58	27.6 (29)	34.9 (29)	.80 (2)	0.25
5	Sick leave or disability	47	22.9 (24)	27.7 (23)		
6	Retired	83	49.5 (52)	37.3 (31)		
7	Education					
8	≤12 years	158	81.1(86)	86.7 (72)	1.07 (1)	0.30
9	≥13 years	31	18.9 (20)	13.3 (11)		
10	Clinical variables		Mean (SD)	Mean (SD)	t (df)	
11	Comorbidities (SCQ)	193	3.72 (3.3)	4.67 (4.0)	-1.74 (161.4)	0.08
12	FEV1 (expected %)	190	76.7 (19.2)	80.4 (22.8)	-1.20 (188)	0.23
13	FVC (expected %)	183	91.2 (15.00)	102.4 (19.4)	t -4.30(149.8)	<.001
14	Symptoms					
15	Fatigue (LFS) baseline	196	2.50 (2.0)	2.48 (2.0)	t -0.07 (194)	0.94
16	Fatigue (LFS) 5-month follow-up	196	3.0 (2.2)	2.9 (2.1)	t 0.32 (194)	0.75
17	Shortness of breath (EORTC)	194	2.24 (0.8)	2.00 (0.7)	t -2.28 (192)	0.023
18	Cough (EORTC)	193	1.96 (0.7)	1.98 (0.8)	t -0.11 (191)	0.92
19	Depression (CES-D)	190	10.49 (8.8)	12.92 (8.8)	t -1.89 (188)	0.06
20	Anxiety (STAI)	192	51.22 (3.1)	50.80 (2.9)	t 0.96 (190)	0.34
21	Sleep disturbance (GSDS)	191	2.26 (1.05)	2.32 (1.00)	t -0.36 (189)	0.72
22	Pain (BPI) yes	171	40.0 (38) % (n)	51.3 (39) % (n)	χ (df) 2.18 (1)	p-value 0.14
23	Pathology and treatment					
24	Tumor type					
25	Adenocarcinoma	106	45.0 (50)	65.9 (56)	24.00 (4)	<.001
26	Squamous cell	66	45.0 (50)	12.9 (11)		
27	Small cell	5	1.8 (2)	3.5 (3)		
28	Carcinoid	6	1.8 (2)	4.7 (4)		
29	Other	18	6.3 (7)	12.9 (11)		
30	Stage of cancer disease					
31	IA	58	25.2 (27)	41.3 (31)	9.12 (4)	0.06
32	IB	59	35.5 (38)	28.0 (21)		
33	II	35	24.3 (26)	12.0 (9)		
34	IIIA	31	14.0 (15)	18.7 (14)		
35	IIIB-IV	1	0.9 (1)	-		
36	Preoperative treatment					
37	None	192	97.3 (108)	98.8 (84)	1.58 (3)	0.66
38	Radiation	1	0.9 (1)	-		
39	Chemotherapy	1	0.9 (1)	-		
40	Combination	2	0.9 (1)	1.2 (1)		
41	Type of surgery					
42	Lobectomy	133	67.6 (75)	68.2 (58)	1.26 (4)	0.87
43	Bilobectomy	15	6.3 (7)	9.4 (8)		
44	Pneumonectomy	18	9.0 (10)	9.4 (8)		
45	Wedge resection	18	9.9 (11)	8.2 (7)		
46	Thoracoscopic	12	7.2 (8)	4.7 (4)		
47	Postoperative complications					
48	Reoperation	9	3.6 (4)	5.9 (5)	0.57 (1)	0.45
49	Pneumonia	50	27 (30)	23.8 (20)	0.26 (1)	0.61
50	Posttreatment					
51	Radiation therapy	16	9.9 (11)	5.9 (5)	1.04 (1)	0.31
52	Chemotherapy	57	30.6 (34)	27.1 (23)	0.30 (1)	0.59
53	Physiotherapy	58	24.3 (26)	38.1 (32)	4.24 (1)	0.04
54	Rehabilitation	24	7.5 (8)	19.3 (16)	5.90 (1)	0.015

Abbreviations: SCQ, Self-administered Comorbidity Questionnaire; FEV1, forced expiratory volume in one second; FVC, Forced vital Capacity; EORTC, European Organization for Research and Treatment of Cancer; CES-D, Center for Epidemiologic Studies – Depression Scale; STAI, State-Trait Anxiety Inventory; GSDS, General Sleep Disturbance Scale; BPI, Brief Pain Inventory; LFS, Lee Fatigue Inventory.

Notes: Fatigue, range 0–10, higher score indicating greater fatigue severity; shortness of breath and cough range 1–4, higher score indicating more shortness of breath and cough; depression, range 0–60, higher score indicating more depression; pain, range 0–10, higher score indicating more pain; comorbidity, range 0–57, higher score indicating more comorbidity; anxiety, range 20–80, higher score indicating more anxiety; sleep disturbance, range 0–7, higher score indicating more severe sleep disturbance.

Bold numbers represent significant relationships.

3.2. Bivariate analyses

The bivariate analyses between the symptom variables are shown in Table 2. Medical and treatment characteristics including cancer stage, tumor type, type of surgery, and postoperative treatment such as radiation therapy, chemotherapy, physiotherapy, and rehabilitation were not significantly correlated with either preoperative or postoperative fatigue and, thus, were not included in the final model. Sociodemographic variables including work, education, and cohabitation were excluded before the final analyses for the same reason.

Table 2
Correlation matrix for symptoms at baseline, and fatigue baseline and 5-month follow-up (N=196).

	1	2	3	4	5	6	7	8	9	10	11	12	13
1 Age	1												
2 Gender	-.16*	1											
3 FEV1	.06	.09	1										
4 FVC	.02	.31*	.65*	1									
5 Fatigue (LFS) baseline	-.23*	-.01	-.19*	-.14	1								
6 Fatigue (LFS) 5-month follow-up	-.16*	-.02	-.22*	-.17*	.52*	1							
7 Comorbidities (SCQ)	.04	.13	-.23*	-.12	.29*	.31*	1						
8 Shortness of breath (EORTC)	-.03	-.16*	-.25*	-.24*	.35*	.62*	.31*	1					
9 Cough (EORTC)	-.04	.01	-.14	-.15*	.33*	.33*	-.04	.17*	1				
10 Depression (CES-D)	-.15*	.14	-.07	-.03	.47*	.31*	.17*	.17*	.12	1			
11 Anxiety (STAI)	.06	-.07	.08	-.00	-.24*	-.12	-.08	-.01	-.1	-.28*	1		
12 Sleep disturbance (GSDS)	-.22*	.03	-.09	-.08	.50*	.41*	.18*	.26*	.14	.57*	-.22*	1	
13 Pain (BPI)	.1	-.11	.09	.1	-.25*	-.23*	-.18*	-.15	-.02	-.08	.18*	-.23*	1

* Correlation is significant at the 0.05 level (2-tailed).

Abbreviations: SCQ, Self-administered Comorbidity Questionnaire; FEV1, Forced expiratory volume in one second; FVC, Forced vital Capacity; EORTC, European Organization for Research and Treatment of Cancer; CES-D, Center for Epidemiologic Studies – Depression Scale; STAI, State-Trait Anxiety Inventory; GSDS, General Sleep Disturbance Scale; BPI, Brief Pain Inventory; LFS, Lee Fatigue Inventory.

3.3. Multivariate analyses

Hierarchical multiple regression analyses were used to assess the impact of the selected variables on levels of preoperative and postoperative fatigue (Table 3). Age, sex, and clinical variables were unrelated to preoperative fatigue.

Table 3

Results from the two hierarchical multivariate linear regression analyses with preoperative fatigue and postoperative fatigue (at 5-month follow-up) were used as dependent variables (N=196).

	Preoperative fatigue			Postoperative fatigue		
	Beta	β	p-value	Beta	β	p-value
Sociodemographics						
Age	-0.04	-0.14	0.13	-0.02	-0.07	0.26
Gender	-0.39	-0.10	0.16	0.03	0.01	0.93
Explained variance (R ²)		5.5%	0.01		2.9%	0.10
Clinical variables						
FEV1	-0.00	-0.05	0.63	-0.00	-0.03	0.71
FVC	-0.01	0.04	0.61	0.00	0.04	0.65
Comorbidity	0.10	0.18	0.008	0.05	0.08	0.19
R ² change		10.6%	<0.001		12.1%	<0.001
Explained variance		16.1			15.0	
Fatigue at baseline						
Fatigue				0.18	0.17	0.03
R ² change					16.2%	<0.001
Explained variance					31.2%	
Other symptoms at baseline						
Shortness of breath	0.33	0.13	0.06	1.27	0.46	<0.001
Cough	0.64	0.25	<0.001	0.50	0.18	0.004
Depression	0.05	0.23	0.003	0.01	0.04	0.63
Anxiety	-0.05	-0.07	0.29	0.00	0.00	0.95
Sleep disturbance	0.02	0.20	0.01	0.01	0.11	0.12
Pain	0.44	0.20	0.01	-0.29	-0.07	0.26
R ² change		30.5%	<0.001		23.2%	<0.001
Explained variance		46.6%			54.3%	

Abbreviations: FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity.

Note: Bold numbers represent significant relationships.

1
2
3 At baseline, patients who reported pain scored higher on fatigue (M=2.9, SD=2.05)
4 compared with patients who reported no pain (M=2.03, SD=1.8, t=3.28, p=0.001). Patients
5 who reported pain at baseline also reported higher mean fatigue at five-month follow-up
6 (M=3.54, SD=2.21) compared with those who reported no pain at baseline (M=2.55,
7 SD=2.04, t=3.08, p=0.002). Among the reported symptoms, coughing, depression, sleep
8 disturbance, and pain interference were related to preoperative fatigue after controlling for
9 age, sex, clinical variables, and the other symptoms. The total model explained 46.6% of
10 variance, while 30.5% was explained by the other symptoms.
11
12
13
14
15
16
17
18
19
20

21 At five-month follow-up, the only variables that predicted fatigue after controlling for
22 age, sex, clinical variables, preoperative fatigue, and symptoms were shortness of breath and
23 coughing. The total model explained 54.3% of variance, while 23.2% was explained by the
24 other symptoms.
25
26
27
28
29
30

31 **4. Discussion**

32 To our knowledge, this is the first study examining fatigue in surgically treated LC
33 patients, including both preoperative data and data from five-month follow-up. Preoperative
34 fatigue was significantly correlated with comorbidities and all the included symptoms in the
35 bivariate analyses, while postoperative fatigue was significantly correlated with comorbidities
36 and four out of six measured symptoms. However, shortness of breath was the only baseline
37 variable that predicted postoperative fatigue.
38
39
40
41
42
43
44
45
46
47
48

49 *4.1. Relationship between postoperative fatigue level and preoperative symptoms*

50 Shortness of breath, coughing, depression, anxiety, sleep disturbance, and pain
51 interference were significantly correlated with level of preoperative fatigue. Except for
52 anxiety and pain interference, the same symptoms were associated with postoperative fatigue
53 in the bivariate analyses at five-month follow-up. Before surgery, cough was significantly
54
55
56
57
58
59
60

1
2
3 associated with fatigue, while shortness of breath was the symptom predictive of
4
5 postoperative fatigue. Shortness of breath is a prevalent and disturbing symptom in these
6
7 patients, which is physiologically based on disease location, damage caused by lung tumors,
8
9 and history of smoking. Shortness of breath requires intensive effort to breath, thus making
10
11 patients tired. The constant use of rib and respiratory muscles caused by shortness of breath
12
13 can exacerbate fatigue,[38]. These patients may benefit from prescribed bronchodilators and
14
15 non-pharmacological treatment such as physical activity. For some, it may be useful to learn
16
17 how to manage shortness of breath by controlled breathing techniques and practicing calming
18
19 techniques during shortness of breath episodes.
20
21
22

23
24 Consistent with previous research, we found that fatigue in LC patients undergoing
25
26 surgery is correlated with their symptoms and might cluster with other symptoms,[2,39].
27
28 Cheville et al.,[2] found a cluster of fatigue, cough, and dyspnea in LC survivors lasting for
29
30 eight years; however, in a later study, the same group found that the cluster did not predict
31
32 patient outcomes but that fatigue and dyspnea, alone and together, were sufficient to predict
33
34 important outcomes,[8].
35
36
37

38 39 *4.2. Relationship between fatigue and patients' disease characteristics and treatment*

40
41 Although comorbidities did not predict postoperative fatigue in our analyses, there was
42
43 a bivariate relationship with fatigue both pre- and postoperatively. Others have also reported
44
45 correlations between comorbidity and fatigue,[6,12]. Respiratory comorbidities and cardiac
46
47 disease are especially related to fatigue in LC patients,[3,40]. We also found a correlation
48
49 between fatigue and spirometry results, with lower FEV1 and FVC related to higher levels of
50
51 fatigue at both measurement times. These variables were related to comorbidity and are an
52
53 important factor in identifying and screening patients at risk for developing fatigue. Poorer
54
55 respiratory test outcomes could indicate shortness of breath or respiratory comorbidities, such
56
57 as COPD, and may lead to distress and exhaustion and contribute to fatigue in these patients.
58
59
60

1
2
3 Surgery type has been established as a predictor of fatigue in LC survivors and surgery
4 has been associated with a greater symptom burden generally,[19]. In the present study,
5
6 treatment and disease variables did not correlate with postoperative fatigue at five-month
7
8 follow-up. These findings are inconsistent with other reports in which correlations have been
9
10 found between fatigue and chemotherapy,[9] and radiotherapy,[11]. However, our findings
11
12 are consistent with those from a general cancer population on the symptom cluster of pain,
13
14 fatigue, sleep disturbance, and depression. That group found that symptom experiences were
15
16 independent of demographic, disease, or treatment effects; their findings suggest that different
17
18 subgroups of patients may harbor different determinants (e.g., genetic) for experiencing
19
20 symptoms and suggested etiology that are independent of demographic, disease, or treatment
21
22 characteristics,[41].
23
24
25
26
27
28

29 *4.3. Limitations*

30
31
32 Some study limitations need to be acknowledged. There was a five-month gap between
33
34 the two measurement points. During this time, other factors might have influenced patients'
35
36 fatigue experience. Surgery type might also be a predictor of patient fatigue,[19]. In this
37
38 study, only 6% of patients had video-assisted thoracoscopy; thus, it is not possible to
39
40 determine whether this influenced postoperative fatigue. Detailed information on symptom
41
42 management interventions such as physiotherapy and rehabilitation was not collected.
43
44 However, even if these variables had been included, no detailed information about the type
45
46 and length of these therapies was available.
47
48
49
50

51 **5. Conclusions**

52
53
54 Based on the findings in the present study, patients should be screened for symptoms
55
56 before surgery and offered treatment for their symptoms to reduce pre- and postoperative
57
58 fatigue. Special attention should be given to treating patients' shortness of breath, since this is
59
60

1
2
3 a modifiable predictor for which treatments are available. Further research should pay specific
4
5 attention to the pair of symptoms of shortness of breath and fatigue, and to the effects on
6
7 fatigue and QOL when shortness of breath is treated.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Acknowledgements

We thank all of the patients who kindly participated and the nurses and physicians at Oslo University Hospital, St. Olav University Hospital, and Haukeland University Hospital who facilitated data collection.

Footnotes

Contributors: TR and TO conceptualised the study. TO wrote the protocol manuscript and TR contributed to protocol development. TO had responsibility for data collection. TH and AL conducted the data analyses and drafted the initial report. TO and TR critically reviewed and edited the manuscript. All authors read and approved the final manuscript. Each author contributed to interpreting the analyses and to critically revising the article, and approved the final draft.

Funding: The study was funded by the Norwegian Cancer Association.

Patient consent: Not required.

Ethics approval The Regional Ethics Committee for the South-East 2010/1508, and the Institutional Review Boards (Personvernombudet) at each hospital approved the study. Each participant received written information about the study and signed informed consent.

Competing interests: None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

References

- 1 Krefregisteret 2017 [updated 09.05.2017]. Available from <https://www.krefregisteret.no/Registrene/Krefstatistikk/en/>
- 2 Cheville AL, Novotny PJ, Sloan JA et al. Fatigue, dyspnea, and cough comprise a persistent symptom cluster up to five years after diagnosis with lung cancer. *J Pain Symptom Manage* 2011;42:202–212. <https://doi.org/10.1016/j.jpainsymman.2010.10.257>.
- 3 Hung R, Krebs P, Coups EJ, et al. Fatigue and functional impairment in early-stage non-small cell lung cancer survivors. *J Pain Symptom Manage* 2011;41:426–435. <https://doi.org/10.1016/j.jpainsymman.2010.05.017>.
- 4 Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and Management. *Oncologist* 1991;4:1–10. DOI: 10.1097/01893697-200119020-00038 · S.
- 5 Lee KA, Hicks G, Nino-Murcia G, Validity and reliability of a scale to assess fatigue. *Psychiatry Res* 1990;36:291–298. [https://doi.org/10.1016/0165-1781\(91\)90027-M](https://doi.org/10.1016/0165-1781(91)90027-M).
- 6 Carnio S, Di Stefano RF, Novello S. Fatigue in lung cancer patients: symptom burden and management of challenges. *Lung Cancer (Auct)* 2016;7:73–82. doi: 0.2147/LCTT.S85334.
- 7 Sarna L, Padilla G, Holmes C, et al. Quality of life of long-term survivors of non-small-cell lung cancer. *J. Clin Oncol* 2002;20:2920–2929. <https://doi.org/10.1200/JCO.2002.09.045>.
- 8 Cheville AL, Novotny PJ, Sloan JA, et al. The value of a symptom cluster of fatigue, dyspnea, and cough in predicting clinical outcomes in lung cancer survivors. *J Pain Symptom Manag* 2011;42:213–221. <https://doi.org/10.1016/j.jpainsymman.2010.11.005>.
- 9 Long NH, Thanasilp S, Thato R. A causal model for fatigue in lung cancer patients receiving chemotherapy. *Eur J Oncol Nurs* 2016;21:242-247. <https://doi.org/10.1016/j.ejon.2015.10.010>.
- 10 Molassiotis A, Lowe M, Blackhall F, et al. A qualitative exploration of a respiratory distress symptom cluster in lung cancer: cough, breathlessness and fatigue. *Lung Cancer* 2011;71:94–102. <https://doi.org/10.1016/j.lungcan.2010.04.002>.
- 11 Ozturk A, Sarihan S, Ercan I, et al. Evaluating quality of life and pulmonary function of long-term survivors of non-small cell lung cancer treated with radical or postoperative radiotherapy. *Am J Clin Oncol* 2009;32:65-72. doi: 10.1097/COC.0b013e31817e6ec2.
- 12 Sarna L, Cooley ME, Brown JK, et al. Symptom severity 1 to 4 months after thoracotomy for lung cancer. *Am J of Crit Care* 2008;17:455-467.
- 13 Poghosyan H, Sheldon LK, Leveille SG, et al. Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: a systematic review. *Lung Cancer* 2013;81:11-26. <https://doi.org/10.1016/j.lungcan.2013.03.013>.
- 14 Hoffman AJ, Given BA, von Eye A, et al. Relationships among pain, fatigue, insomnia, and gender in persons with lung cancer. *Oncol Nurs Forum* 2007;34:785. <http://ezproxy.diastud.no/docview/223105953?accountid=37793>.
- 15 Wright F, Melkus GDE, Hammer M, et al. Trajectories of evening fatigue in oncology

- 1
2
3 outpatients receiving chemotherapy. *J Pain Symptom Manag* 2015;50:163-175.
4 <https://doi.org/10.1016/j.jpainsymman.2015.02.015>.
5
- 6 16 Wright F, Melkus GDE, Hammer M, et al. Predictors and trajectories of morning fatigue
7 are distinct from evening fatigue. *J Pain Symptom Manag* 2015;50:176-189.
8 <https://doi.org/10.1016/j.jpainsymman.2015.02.016>
9
- 10 17 Storey DJ, Waters RA, Hibberd CJ, et al. Clinically relevant fatigue in cancer outpatients:
11 the Edinburgh Cancer Centre symptom study. *Ann Oncol* 2007;18:1861-1869.
12 <https://doi.org/10.1093/annonc/mdm349>.
13
- 14 18 Huang X, Zhou W, Zhang Y. Features of fatigue inpatients with early-stage non-small
15 cell lung cancer. *J Res Med Sci*; 2015;20:268–272.
16
- 17 19 Yang P, Chevillat AL, J.A. Wampfler JA, et al., Quality of life and symptom burden among
18 long term lung cancer survivors: changing and adapting, *J Thorac Oncol* 2012;7:64–70.
19 <https://doi.org/10.1097/JTO.0b013e3182397b3e>.
20
- 21 20 Oksholm T, Rustoen T, Cooper B, et al. Trajectories of symptom occurrence and severity
22 from before through five months after lung cancer surgery. *J Pain Symptom Manag* 2015;
23 49:995–1015. <https://doi.org/10.1016/j.jpainsymman.2014.11.297>.
24
- 25 21 Oksholm T, Miaskowski C, Solberg S, et al., Changes in symptom occurrence and
26 severity before and after lung cancer surgery, *Cancer Nurs* 2015;38:351–357. doi:
27 10.1097/NCC.000000000000198.
28
- 29 22 Oksholm T, Miaskowski C, J.S. Kongerud JS, et al. Does age influence the symptom
30 experience of lung cancer patients prior to surgery? *Lung Cancer* 2013;82:156–161.
31 <https://doi.org/10.1016/j.lungcan.2013.06.016>.
32
- 33 23 Sangha O, Stucki G, Liang MH, et al. The Self-Administered Comorbidity Questionnaire: a
34 new method to assess comorbidity for clinical and health services research. *Arthrit Care Res*
35 2003;49:156–163. <https://doi.org/10.1002/art.10993>.
36
- 37 24 Miaskowski C, Lee KA. Pain, fatigue, and sleep disturbances in oncology outpatients
38 receiving radiation therapy for bone metastasis: a pilot study. *J Pain Symptom Manag*
39 1999;17:320–332. [https://doi.org/10.1016/S0885-3924\(99\)00008-1](https://doi.org/10.1016/S0885-3924(99)00008-1).
40
- 41 25 Lerdal A, Kottorp A, Gay CL, et al. Lee Fatigue and Energy Scales: exploring
42 aspects of validity in a sample of women with HIV using an application of a Rasch model,
43 *Psychiatry Res* 2013;205;241–246. <https://doi.org/10.1016/j.psychres.2012.08.031>.
44
- 45 26 Bergman B, Aaronson N, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular
46 supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in
47 lung cancer clinical trials. *Eur J Cancer* 1994;30:635–642. [https://doi.org/10.1016/0959-8049\(94\)90535-5](https://doi.org/10.1016/0959-8049(94)90535-5).
48
- 49 27 Giesinger JM, Kieffer JM, Fayers PM, et al. Replication and validation of higher order
50 models demonstrated that a summary score for the EORTC QLQ-C30 is robust. *J Clin*
51 *Epidemiol* 2016;69:79–88. <https://doi.org/10.1016/j.jclinepi.2015.08.007>.
52
- 53 28 Michelson H, Bolund C, Nilsson B, et al. Health-related quality of life
54 measured by the EORTC QLQ-C30: reference values from a large sample of the Swedish
55 population. *Acta Oncol* 2000;39:477–484. <https://doi.org/10.1080/028418600750013384>
56
57
58
59
60

- 1
2
3 29 Radloff LS. The CES-D scale: a self-report depression scale for the general population, *Appl Psych Mea*. 1977;1:385–401. <https://doi.org/10.1177/014662167700100306>
- 4
5
6 30 Sheehan JT, Fifield J, Reisine S, et al. The measurement structure of the Center
7 for Epidemiologic Studies Depression Scale. *J Pers Assess* 1995;64:507-521.
8 https://doi.org/10.1207/s15327752jpa6403_9.
- 9
10 31 Spielberger CD, Gorsuch RC, Lushene RE, et al. Manual for the
11 State-Trait Anxiety Inventory (Form Y): Self-Evaluation Questionnaire. Consulting
12 Psychologists Press, Palo Alto, CA, 1983.
- 13
14 32 Cataldo JK, Brodsky JL. Lung cancer stigma, anxiety, depression and symptom
15 Severity. *Oncology* 2013;85:33–40. <https://doi.org/10.1159/000350834>
- 16
17 33 Lee KA. Self-reported sleep disturbances in employed women. *Sleep* 1992;15:493-
18 498. <https://doi.org/10.1093/sleep/15.6.493>.
- 19
20 34 Cleeland CS, Measurement and prevalence of pain in cancer. *Seminars in Onc Nurs*
21 1985;1:87–92. [https://doi.org/10.1016/S0749-2081\(85\)80041-3](https://doi.org/10.1016/S0749-2081(85)80041-3).
- 22
23 35 Klepstad P, Loge JH, Borchgrevink PC, et al. The Norwegian Brief Pain Inventory
24 Questionnaire: translation and validation in cancer pain patients. *J Pain Symptom Manag*
25 2002;24: 517–525. [https://doi.org/10.1016/S08853924\(02\)00526-2](https://doi.org/10.1016/S08853924(02)00526-2).
- 26
27 36 Cohen J. A power primer: quantitative methods in psychology. *Psychological Bulletin*
28 1992;112:155-159. doi:10.1037/0033-2909.112.1.155
- 29
30 37 Soper DS. Post-hoc statistical power calculator for hierarchical multiple regression
31 (Software) 2017. Available from: <http://www.danielsoper.com/statcalc/references.aspx?id=17>.
- 32
33 38 Esper P, Heidrich D, Symptom clusters in advanced illness. *Seminars in Oncology*
34 *Nursing* 2005;25:20–28. <https://doi.org/10.1053/j.soncn.2004.10.004>.
- 35
36 39 Lin S, Chen Y, Yang L, et al. Pain, fatigue, disturbed sleep and distress comprised a
37 symptom cluster that related to quality of life and functional status of lung cancer surgery
38 patients. *J Clinical Nurs* 2013; 22.9-10:1281–1289. <https://doi.org/10.1111/jocn.12228>
- 39
40 40 Yun YH, Kim YA, Min YH, et al., Health-related quality of life in disease-free survivors of
41 surgically treated lung cancer compared with the general population, *Ann Surg*
42 2012;255:1000–1007. doi: 10.1097/SLA.0b013e31824f1e9e.
- 43
44 41 Miaskowski C, Cooper BA, Paul SM, et al. Subgroups of patients with cancer with
45 different symptom experiences and quality-of-life outcomes: a cluster analysis. *Oncol Nurs*
46 *Forum* 2006;33.
- 47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for case report or case series.

Based on the CARE guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the CARE reporting guidelines, and cite them as:

Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development

	Reporting Item	Page Number
	#1 The area of focus and "case report" should appear in the title	1
	#2 Two to five key words that identify topics in this case report	2
Introduction	#3a What is unique and why is it important?	2
	#3b The patient's main concerns and important clinical findings.	2
	#3c The main diagnoses, interventions, and outcomes.	2

1	Conclusion	#3d	What are one or more “take-away” lessons?	2
2				
3				
4		#4	Briefly summarize why this case is unique with medical	3,4
5			literature references.	
6				
7				
8				
9				
10		#5a	De-identified demographic and other patient information.	5
11				
12				
13		#5b	Main concerns and symptoms of the patient.	6,7
14				
15				
16		#5c	Medical, family, and psychosocial history including genetic	5,6
17			information.	
18				
19				
20				
21		#5d	Relevant past interventions and their outcomes.	5
22				
23				
24		#6	Relevant physical examination (PE) and other clinical findings.	10
25				
26				
27		#7	Relevant data from this episode of care organized as a timeline	115
28			(figure or table).	
29				
30				
31				
32				
33		#8a	Diagnostic methods (PE, laboratory testing, imaging, surveys).	5
34				
35				
36		#8b	Diagnostic challenges.	5
37				
38				
39		#8c	Diagnostic reasoning including differential diagnosis	5
40				
41				
42		#8d	Prognostic characteristics when applicable	5
43				
44				
45		#9a	Types of intervention (pharmacologic, surgical, preventive).	5
46				
47				
48		#9b	Administration of intervention (dosage, strength, duration)	5
49				
50				
51		#9c	Changes in the interventions with explanations.	5
52				
53				
54		#10a	Clinician and patient-assessed outcomes when appropriate	11,12
55				
56				
57		#10b	Important follow-up diagnostic and other test results.	11,12
58				
59				
60				

1	#10c	Intervention adherence and tolerability (how was this	12
2		assessed)?	
3			
4			
5			
6	#10d	Adverse and unanticipated events.	11
7			
8			
9			
10	#11a	Strengths and limitations in your approach to this case.	3
11			
12			
13	#11b	Discussion of the relevant medical literature.	13,14
14			
15			
16	#11c	The rationale for your conclusions.	13,14
17			
18			
19	#11d	The primary “take-away” lessons from this case report.	14,15
20			
21			
22	#12	The patient can share their perspective on their case	12,13
23			
24			
25	#13	The patient should give informed consent.	8
26			
27			

28 The CARE checklist is distributed under the terms of the Creative Commons Attribution License CC-
29 BY-NC. This checklist was completed on 26. November 2018 using <http://www.goodreports.org/>, a
30 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Predicting postoperative fatigue in surgically treated lung cancer patients – a longitudinal five-month follow-up study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028192.R1
Article Type:	Original research
Date Submitted by the Author:	01-Jun-2019
Complete List of Authors:	Hugoy, Therese ; University of Oslo, Institute of Health and Society, Faculty of Medicine, ; Lovisenberg Diakonale Hogskole Lerdal, Anners; University of Oslo, Dept. of Nursing Science; Lovisenberg Diakonale Hospital, Dept. of Research Rustoen, Tone; University of Oslo, Norway, Institute of Health and Society, Faculty of Medicine; Oslo universitetssykehus Ulleval, Department of Research and Development, Division of Emergencies and Critical Care Oksholm, Trine; VID Vitenskapelige Hogskole, Faculty of Health Studies, Campus Haraldsplass
Primary Subject Heading:	Nursing
Secondary Subject Heading:	Oncology, Surgery
Keywords:	Fatigue, Lung Cancer, Neoplasm, Quality of Life, SURGERY

SCHOLARONE™
Manuscripts

1
2
3 **Predicting postoperative fatigue in surgically treated lung cancer patients – a**
4 **longitudinal five-month follow-up study.**
5
6

7 Therese Hugøy^{a,b,c}, Anners Lerdal^{a,d} Tone Rustøen^{a,e}, Trine Oksholm^f
8
9

10
11 ^aDepartment of Nursing Science, Institute of Health and Society, Faculty of Medicine,
12 University of Oslo, Norway.
13

14 ^bCentre for Patient centered heart- and lung research. Department of cardiothoracic surgery.
15 Division of Cardiovascular and Pulmonary Diseases. Oslo University Hospital, Oslo, Norway.
16 (T.H.)
17

18
19 ^cLovisenberg Diaconal University College, Lovisenberggt. 15B, 0456 Oslo
20

21 ^dDepartment for Patient Safety and Research, Lovisenberg Diaconal Hospital, P.O. Box 4970
22 Nydalen, 0440 Oslo, Norway
23

24
25 ^eDepartment of Research and Development, Division of Emergencies and Critical Care, Oslo
26 University Hospital, P.O. Box 4956 Nydalen, 0424 Oslo, Norway;
27

28 ^fVID Specialized University, Faculty of Health Studies, Campus Haraldsplass, P.O. Box 184
29 Vinderen, 0319 Oslo, Norway
30
31

32
33
34 *Corresponding author at:
35 Trine Oksholm
36 trine.oksholm@vid.no
37
38

39
40
41
42 Word count: 3275
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Despite the negative influence of fatigue on quality of life in patients who undergo lung cancer surgery, little is known about the possible predictors of postoperative fatigue. The aim of this study was to examine demographic and clinical characteristics that might predict postoperative fatigue five months after lung cancer surgery.

Design: A prospective longitudinal follow up study comprising pre- and postoperative questionnaires, including Lee Fatigue Scale, and sociodemographic and clinical data.

Setting: Three university hospitals in Norway (e.g., Oslo University Hospital, St. Olav University Hospital, Haukeland University Hospital).

Participants: In total, 196 surgically treated patients who answered the questionnaires both preoperatively and at five-month follow-up with valid fatigue scores.

Results: Bivariate analyses showed that preoperative fatigue was associated with comorbidities and the symptoms of shortness of breath, cough, depression, anxiety, sleep disturbance, and pain. Only cough was directly associated with preoperative fatigue in a regression model. Comorbidities and the symptoms of shortness of breath, cough, depression, and sleep disturbance were associated with postoperative fatigue in the bivariate analyses, but only shortness of breath was associated with postoperative fatigue in the regression model. We did not find any significant correlations between fatigue and any treatment variable.

Conclusion: Clinicians should pay special attention to lung symptoms and be aware that these may lead to long-term postoperative fatigue. Further research should examine whether interventions reducing lung symptoms, such as shortness of breath and coughing, may prevent development of fatigue in patients undergoing lung cancer surgery.

Key words: Fatigue, Lung Cancer, Neoplasm, Quality of Life, Surgery

Strengths and limitations of this study

- Fatigue is a symptom that has a great impact on patients quality of life and this topic is relevant both to patients and healthcare providers
- A rather large sample of surgically treated lung cancer patients were included in the study patients', fatigue was measured both preoperatively and after surgery. This gives information about fatigue after lung cancer surgery.
- There was a five-month gap between the two measurement points. During this time, other factors might have influenced patients' fatigue experience.
- There were limited information on symptom management interventions such as physiotherapy and rehabilitation

1. Introduction

Lung cancer (LC) is presently one of the most common malignancies, and it is estimated that 20% of cancer-related deaths are caused by LC.[1] Only 20% of patients diagnosed with non-small-cell lung cancer meet the criteria for surgery due to their late stage at diagnosis; for these patients, surgery may be curative.[2] In Norway during 2014, five-year LC survival was generally 19% in women and 13% in men.[1] In surgically treated patients, the five-year survival ranges from 50% to 70%, depending on the tumor stage at surgery.

Fatigue is common among cancer patients. An estimated 75–90% of patients with LC report fatigue after cancer treatment.[3,4] Fatigue has been described as a complex, multidimensional symptom and has been defined as a sense of exhaustion, lack of energy, or tiredness distinct from sleepiness, sadness, or weakness.[5] Cancer-related fatigue is related to cancer or its treatment, and interferes with usual functioning.[3] Fatigue has a negative impact on patients' health-related quality of life (HRQOL),[6] their ability to receive treatment, and their long-term prognosis. Although there are limited data on LC and fatigue in patients who have undergone surgery, it has been shown that fatigue has a negative impact on HRQOL in

1
2
3 LC survivors.[7] One study showed that fatigue was a significant predictor of survival at each
4 time point assessed.[8] In another study on symptom severity after thoracotomy, fatigue was
5 reported as the most common and severe symptom at every time point.[7]
6
7
8
9

10 Several studies have reported interrelations between fatigue, cough, and dyspnea.[8–11]
11 Fatigue is also strongly related to symptoms of depression and anxiety.[12,13] Associations
12 between fatigue and sex, pain, insomnia, and dyspnea have also been reported.[12,14] Studies
13 on fatigue in populations with lung cancer in different stages have also shown strong
14 correlations between fatigue and sleep disturbance.[6,15–17] Sarna et al.,[12] found that
15 symptom severity in surgical patients was related to the extent of their comorbid condition.
16 Other studies of patients with LC have also shown correlations between comorbidities and
17 fatigue,[6] as well as strong correlations between pulmonary diseases such as COPD and
18 asthma, and fatigue.[3,18] Studies of fatigue in the general population has shown a higher
19 proportion of severe fatigue cases among women than among men.[19,20] Thus, examining
20 differences in fatigue in relation to sex among LC patients is of interest. Fatigue has a
21 negative impact on both patients with LC and survivors in general;[21] however, to our
22 knowledge, there have been no studies to date specifically investigating fatigue in surgically
23 treated patients with LC.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Thus, our aim was to examine the relationships between fatigue and disease
43 characteristics, treatment, and other symptoms. We hypothesized that fatigue levels at five-
44 month follow-up would be significantly related to: (1) sex, (2) clinical variables (preoperative
45 comorbidities, forced expiratory volume in one second [FEV1], and forced vital capacity
46 [FVC]); (3) preoperative symptoms (shortness of breath, coughing, depression, anxiety, pain,
47 and sleep disturbance); and (4) treatment and medical variables (surgery type, cancer stage,
48 and adjuvant therapy).
49
50
51
52
53
54
55
56
57
58
59

60 **2. Material and methods**

1
2
3 This study is part of a larger, longitudinal investigation of symptoms in patients with LC
4 who were eligible for surgery,[22–24] for which data were collected prior to surgery and
5 prospectively at four time points up to one year after surgery. Here, we analyzed the data
6 collected prior to surgery and at the five-month follow-up to gain insight into patients'
7 experiences with fatigue before surgery and after the immediate postoperative period.
8
9
10
11
12
13
14

15 16 *2.1. Patients and settings*

17
18 Patients were included if they were 18 years or older, scheduled for primary LC surgery,
19 and could understand, read, and write Norwegian. Patients with a benign or metastatic
20 disease, whose surgery was canceled, or who had cognitive impairment, were excluded. We
21 recruited patients from three university hospitals in Norway: Oslo University Hospital, St.
22 Olav University Hospital, and Haukeland University Hospital. The recruitment started in
23 November 2010 and was completed in March 2012.
24
25
26
27
28
29
30
31
32
33

34 35 *2.2 Patient and Public Involvement*

36
37 The study was funded Norwegian Cancer Society (NCS). The study was discussed with
38 representatives from the Lung Cancer subgroup before the study started and an article about
39 the main result from the study is published in the membership journal for patients with lung
40 cancer.
41
42
43
44
45
46

47 48 *2.3. Study procedures*

49
50 Hospital research staff approached patients and explained the study purpose: 91% of the
51 participants were recruited in the hospital 1–3 days before surgery, and the remainder in
52 outpatient clinics prior to surgery. Patients signed a written informed consent before they
53 completed several self-report questionnaires with information on sociodemographic and
54 clinical characteristics, and symptoms both prior to surgery and at a five-month follow-up.
55
56
57
58
59
60

1
2
3 Permission to use the questionnaire was obtained from the copyright detectors before study
4 start. Data on type of tumor, cancer stage, surgery type, and lung function were collected from
5 the patients' medical records. FEV1 and FVC were measured preoperatively using a
6 spirometer. Five months after surgery, patients received questionnaires by regular mail, along
7 with a postage-paid return envelope.
8
9
10
11
12
13
14

15 *2.4. Instruments and assessment*

16 *2.4.1. Sociodemographic, clinical, symptom, and fatigue characteristics*

17
18 Patients provided information on their sex, marital status, living situation, level of
19 education, and employment status. Information on age, smoking status, FEV1, tumor
20 histology, cancer stage, type of surgery, pre- and postoperative treatment, postoperative
21 complications, and TNM classification were collected from patients' medical records; the
22 TNM classification is a system for cancer staging based on tumor (T), node (N), and
23 metastasis (M).
24
25
26
27
28
29
30
31
32
33
34

35 *2.4.2. Comorbidities*

36
37 Comorbidities were measured using the Self-administered Comorbidity Questionnaire-
38 19 (SCQ-19),[25] on which scores can range from 0 to 57, with a higher score indicating a
39 more severe comorbidity profile. The SCQ includes 16 comorbidities and three optional
40 conditions. Patients indicated whether or not they had the comorbid condition (yes/no); if they
41 had the condition they were asked if they received treatment for it; and finally if it limited
42 their activities. The SCQ-19 has well-established validity and reliability and has been used to
43 assess comorbidity in Norwegian oncology patients.[25] Only the number of comorbidities
44 was used in the present study.
45
46
47
48
49
50
51
52
53
54

55 *2.4.3. Fatigue*

1
2
3 The Lee Fatigue Scale (LFS),[5] was used to measure fatigue at baseline and five-month
4 follow-up. The LFS consists of 18 items designed to assess fatigue (13 items) and energy (5
5 items). We used only the 13 fatigue items in this study. Patients were asked to rate each item
6 on a 0–10 scale, with a higher score indicating greater fatigue severity. A fatigue score was
7 calculated using the mean of the 13 items at each measurement. The LFS has well-established
8 validity and reliability.[26,27] Fatigue scores at baseline were defined as preoperative fatigue
9 and at five-month follow-up as postoperative fatigue.
10
11
12
13
14
15
16
17
18

19 2.4.4. *Shortness of breath and cough*

20
21 The European Organization for Research and Treatment of Cancer Quality-of-Life
22 Questionnaire – Lung Cancer Module (EORTC QLQ-LC13),[28] was used to measure
23 shortness of breath and cough. Patients were asked to rate their severity on each shortness of
24 breath and cough item using a four-point Likert scale where 1 = not at all; 2 = a little; 3 =
25 quite a bit; and 4 = very much. The EORTC QLQ-LC13 has been validated in Norwegian LC
26 patients.[29,30]
27
28
29
30
31
32
33
34

35 2.4.5. *Depression*

36
37 The Center for Epidemiologic Studies – Depression Scale (CES-D),[31] was used to
38 measure depression symptoms. The scale has 20 items related to depression and patients were
39 asked to report how they felt during the past week. Each item was rated on a four-point Likert
40 scale and scores ranged from 0 to 60, with a higher score indicating a higher level of
41 depression. A total depression score was calculated as the mean of all the sub scores.
42 Acceptable reliability and validity have been reported in a previous study.[32]
43
44
45
46
47
48
49
50
51

52 2.4.6. *Anxiety*

53
54 The State-Trait Anxiety Inventory (STAI, Y-2),[33] was used to measure anxiety. The
55 STAI includes 20 items related to anxiety rated on a four-point Likert scale. Scores range
56
57
58
59
60

1
2
3 from 20 to 80, with a higher score indicating a higher level of anxiety. The STAI has been
4
5 validated in patients with LC.[34]
6
7

8 9 *2.4.7. Sleep disturbance*

10 The General Sleep Disturbance Scale (GSDS),[35] was used to measure sleep
11
12 disturbance. The GSDS consists of 21 items related to sleep disturbance. Each item is rated on
13
14 a numeric rating scale ranging from 0 (never) to 7 (every day). A sleep disturbance score was
15
16 calculated from the mean of all scale items. Higher scores indicate more severe sleep
17
18 disturbance. The GSDS has been validated in cancer patients.[26]
19
20
21

22 23 *2.4.8. Pain*

24 The Brief-Pain Inventory (BPI),[36] was used to measure pain interference. The BPI is
25
26 a multidimensional questionnaire measuring pain intensity (four items), pain interference
27
28 (seven items), pain relief (one item), and pain location (body map). Only pain interference
29
30 was used in the present study. The seven interference items (general activity, normal work,
31
32 walking ability, mood, relationships with other people, sleep, and enjoyment of life) were
33
34 combined into a single interference item. The measurement scale ranges from 0 to 10, with
35
36 higher scores indicating more pain interfering with daily living. The BPI has been validated in
37
38 Norwegian cancer patients.[37]
39
40
41
42
43

44 45 *2.5. Ethics*

46 The Regional Ethics Committee for the South-East 2010/1508, and the Institutional Review
47
48 Boards (Personvernombudet) at each hospital approved the study. Each participant received
49
50 written information about the study and signed informed consent. The article complies with
51
52 the STROBE guidelines.[38]
53
54
55
56

57 58 *2.6. Statistical analyses*

59
60

1
2
3 Descriptive statistics were used to describe the sociodemographic, clinical, and
4
5 treatment characteristics of the patient sample. Differences between sexes were analyzed
6
7 using a chi-squared test for categorical variables and an independent Student's *t* test for the
8
9 continuous variables. One-way ANOVA was used to explore differences within groups on
10
11 levels of pre- and postoperative fatigue. Patients with more than 20% of missing items on the
12
13 LFS were excluded from analyses. If the scales had less than 20% missing, the score were
14
15 calculated from the mean of the particular patient's valid scores. The bivariate relationships
16
17 between symptoms and fatigue at baseline were assessed using Pearson correlation analyses.
18
19 Variables with significant correlation coefficients on bivariate analyses were included in a
20
21 hierarchical linear analyses.
22
23
24
25

26 Two stepwise multivariate regression analyses were performed. In the first analysis,
27
28 preoperative fatigue was the dependent variable. In the second analysis, postoperative fatigue
29
30 was the dependent variable. In both analyses, age and sex were entered in step one. Clinical
31
32 variables including comorbidities, FEV1, and FVC were entered in step two. Finally, the
33
34 symptom variables of shortness of breath, cough, depression, anxiety, sleep disturbance, and
35
36 pain interference were entered in step three. For the second regression analysis, the model
37
38 also included a fourth step in which preoperative fatigue was included as an independent
39
40 variable.
41
42
43
44

45 The entry of variables in different model steps was carried out according to theoretical
46
47 and logical considerations. For all analyses, $p < 0.05$ was considered statistically significant.
48
49 Post hoc statistical power was calculated for hierarchical multiple regression: with an effect
50
51 size (f^2) for set B (five-month follow-up) at 0.15 (medium), [39] 11 predictors in set A and 12
52
53 in set B, a probability level of 0.05, and a sample size of 196, the observed power for the
54
55 addition of set B was 0.95. [40] Data were analyzed using SPSS (IBM Corporation, Armonk,
56
57 NY, USA) version 24.0.
58
59
60

Table 1

Demographic, clinical, and treatment characteristics of the patients (N=196).

	Total	Men	Women	Statistics	p-value
Sociodemographics					
Age in years (mean, SD)	196	66.7 (8.2)	64.1 (7.9)	t 2.28 (194)	0.024
		% (n)	% (n)	χ (df)	
Cohabitation (living with someone)	147	84.0 (89)	(69.0) 58	5.95 (1)	0.015
Work status					
Full or part time	58	27.6 (29)	34.9 (29)	.80 (2)	0.25
Sick leave or disability	47	22.9 (24)	27.7 (23)		
Retired	83	49.5 (52)	37.3 (31)		
Education					
≤12 years	158	81.1(86)	86.7 (72)	1.07 (1)	0.30
≥13 years	31	18.9 (20)	13.3 (11)		
Clinical variables					
		Mean (SD)	Mean (SD)	t (df)	
Comorbidities (SCQ)	193	3.72 (3.3)	4.67 (4.0)	-1.74 (161.4)	0.08
FEV1 (expected %)	190	76.7 (19.2)	80.4 (22.8)	-1.20 (188)	0.23
FVC (expected %)	183	91.2 (15.00)	102.4 (19.4)	t -4.30(149.8)	<.001

3. Results

3.1. Sample characteristics

Statisticians calculated that 300 should be included in the study to ensure sufficient strength. Totally, 375 patients with presumptive primary lung cancer were asked to participate in the study and 307 agreed to participate (Fig 1). Among these, 196 patients who answered the questionnaire both preoperatively and at five-month follow-up and had valid fatigue scores at both measurement points were included in the study. Sample characteristics are shown in Table 1. Although women were younger, more women lived alone, reported higher FVC, less shortness of breath and had a higher proportion of adenocarcinoma cancer type, and was more active in physiotherapy and rehabilitation than men, their level of fatigue did not differ. Most of the sample had adenocarcinoma stage 1A or 1B, received no preoperative treatment and had a lobectomy.

The mean preoperative fatigue scores were 2.49 (SD=2.02) for men and 2.47 (SD=1.96) for women. At the five-month follow-up, the postoperative fatigue scores were 3.0 (SD=2.1) for men and 2.9 (SD=2.1) for women. There were no significant differences in fatigue level preoperatively between those who completed or did not complete the postoperative fatigue scale.

Symptoms						
Fatigue (LFS) baseline	196	2.50 (2.0)	2.48 (2.0)	t -0.07 (194)	0.94	
Fatigue (LFS) 5-month follow-up	196	3.0 (2.2)	2.9 (2.1)	t 0.32 (194)	0.75	
Shortness of breath (EORTC)	194	2.24 (0.8)	2.00 (0.7)	t -2.28 (192)	0.023	
Cough (EORTC)	193	1.96 (0.7)	1.98 (0.8)	t -0.11 (191)	0.92	
Depression (CES-D)	190	10.49 (8.8)	12.92 (8.8)	t -1.89 (188)	0.06	
Anxiety (STAI)	192	51.22 (3.1)	50.80 (2.9)	t 0.96 (190)	0.34	
Sleep disturbance (GSDS)	191	2.26 (1.05)	2.32 (1.00)	t -0.36 (189)	0.72	
		% (n)	% (n)	χ (df)		p-value
Pain (BPI) yes	171	40.0 (38)	51.3 (39)	2.18 (1)		0.14
Pathology and treatment						
Tumor type						
Adenocarcinoma	106	45.0 (50)	65.9 (56)	24.00 (4)		<.001
Squamous cell	66	45.0 (50)	12.9 (11)			
Small cell	5	1.8 (2)	3.5 (3)			
Carcinoid	6	1.8 (2)	4.7 (4)			
Other	18	6.3 (7)	12.9 (11)			
Stage of cancer disease						
IA	58	25.2 (27)	41.3 (31)	9.12 (4)		0.06
IB	59	35.5 (38)	28.0 (21)			
II	35	24.3 (26)	12.0 (9)			
IIIA	31	14.0 (15)	18.7 (14)			
IIIB-IV	1	0.9 (1)	-			
Preoperative treatment						
None	192	97.3 (108)	98.8 (84)	1.58 (3)		0.66
Radiation	1	0.9 (1)	-			
Chemotherapy	1	0.9 (1)	-			
Combination	2	0.9 (1)	1.2 (1)			
Type of surgery						
Lobectomy	133	67.6 (75)	68.2 (58)	1.26 (4)		0.87
Bilobectomy	15	6.3 (7)	9.4 (8)			
Pneumonectomy	18	9.0 (10)	9.4 (8)			
Wedge resection	18	9.9 (11)	8.2 (7)			
Thoracoscopic	12	7.2 (8)	4.7 (4)			
Postoperative complications						
Reoperation	9	3.6 (4)	5.9 (5)	0.57 (1)		0.45
Pneumonia	50	27 (30)	23.8 (20)	0.26 (1)		0.61
Posttreatment						
Radiation therapy	16	9.9 (11)	5.9 (5)	1.04 (1)		0.31
Chemotherapy	57	30.6 (34)	27.1 (23)	0.30 (1)		0.59
Physiotherapy	58	24.3 (26)	38.1 (32)	4.24 (1)		0.04
Rehabilitation	24	7.5 (8)	19.3 (16)	5.90 (1)		0.015

Abbreviations: SCQ, Self-administered Comorbidity Questionnaire; FEV1, forced expiratory volume in one second; FVC, Forced vital Capacity; EORTC, European Organization for Research and Treatment of Cancer; CES-D, Center for Epidemiologic Studies – Depression Scale; STAI, State-Trait Anxiety Inventory; GSDS, General Sleep Disturbance Scale; BPI, Brief Pain Inventory; LFS, Lee Fatigue Inventory.

Notes: Fatigue, range 0–10, higher score indicating greater fatigue severity; shortness of breath and cough range 1–4, higher score indicating more shortness of breath and cough; depression, range 0–60, higher score indicating more depression; pain, range 0–10, higher score indicating more pain; comorbidity, range 0–57, higher score indicating more comorbidity; anxiety, range 20–80, higher score indicating more anxiety; sleep disturbance, range 0–7, higher score indicating more severe sleep disturbance.

Bold numbers represent significant relationships.

3.2. Bivariate analyses

The bivariate analyses between the symptom variables are shown in Table 2. Medical and treatment characteristics including cancer stage, tumor type, type of surgery, and postoperative treatment such as radiation therapy, chemotherapy, physiotherapy, and rehabilitation were not significantly correlated with either preoperative or postoperative

fatigue and, thus, were not included in the final model. Sociodemographic variables including work, education, and cohabitation were excluded before the final analyses for the same reason.

Table 2

Correlation matrix for symptoms at baseline, and fatigue baseline and 5-month follow-up (N=196).

	1	2	3	4	5	6	7	8	9	10	11	12	13
1 Age	1												
2 Sex	-.16*	1											
3 FEV1	.06	.09	1										
4 FVC	.02	.31*	.65*	1									
5 Fatigue (LFS) baseline	-.23*	-.01	-.19*	-.14	1								
6 Fatigue (LFS) 5-month follow-up	-.16*	-.02	-.22*	-.17*	.52*	1							
7 Comorbidities (SCQ)	.04	.13	-.23*	-.12	.29*	.31*	1						
8 Shortness of breath (EORTC)	-.03	-.16*	-.25*	-.24*	.35*	.62*	.31*	1					
9 Cough (EORTC)	-.04	.01	-.14	-.15*	.33*	.33*	-.04	.17*	1				
10 Depression (CES-D)	-.15*	.14	-.07	-.03	.47*	.31*	.17*	.17*	.12	1			
11 Anxiety (STAI)	.06	-.07	.08	-.00	-.24*	-.12	-.08	-.01	-.1	-.28*	1		
12 Sleep disturbance (GSDS)	-.22*	.03	-.09	-.08	.50*	.41*	.18*	.26*	.14	.57*	-.22*	1	
13 Pain (BPI)	.1	-.11	.09	.1	-.25*	-.23*	-.18*	-.15	-.08	-.08	.18*	-.23*	1

* Correlation is significant at the 0.05 level (2-tailed).

Abbreviations: SCQ, Self-administered Comorbidity Questionnaire; FEV1, Forced expiratory volume in one second; FVC, Forced vital Capacity; EORTC, European Organization for Research and Treatment of Cancer; CES-D, Center for Epidemiologic Studies – Depression Scale; STAI, State-Trait Anxiety Inventory; GSDS, General Sleep Disturbance Scale; BPI, Brief Pain Inventory; LFS, Lee Fatigue Inventory.

3.3. Multivariate analyses

Hierarchical multiple regression analyses were used to assess the impact of the selected variables on levels of preoperative and postoperative fatigue (Table 3). Age, sex, and clinical variables were unrelated to preoperative fatigue.

Table 3

Results from the two hierarchical multivariate linear regression analyses with preoperative fatigue and postoperative fatigue (at 5-month follow-up) were used as dependent variables (N=196).

	Preoperative fatigue			Postoperative fatigue		
	Beta	β	p-value	Beta	β	p-value
Sociodemographics						
Age	-0.04	-0.14	0.13	-0.02	-0.07	0.26
Sex	-0.39	-0.10	0.16	0.03	0.01	0.93
Explained variance (R^2)		5.5%	0.01		2.9%	0.10
Clinical variables						
FEV1	-0.00	-0.05	0.63	-0.00	-0.03	0.71
FVC	-0.01	0.04	0.61	0.00	0.04	0.65
Comorbidity	0.10	0.18	0.008	0.05	0.08	0.19
R^2 change		10.6%	<0.001		12.1%	<0.001
Explained variance		16.1			15.0	
Fatigue at baseline						
Fatigue				0.18	0.17	0.03
R^2 change					16.2%	<0.001
Explained variance					31.2%	
Other symptoms at baseline						
Shortness of breath	0.33	0.13	0.06	1.27	0.46	<0.001
Cough	0.64	0.25	<0.001	0.50	0.18	0.004
Depression	0.05	0.23	0.003	0.01	0.04	0.63
Anxiety	-0.05	-0.07	0.29	0.00	0.00	0.95
Sleep disturbance	0.02	0.20	0.01	0.01	0.11	0.12
Pain	0.44	0.20	0.01	-0.29	-0.07	0.26
R^2 change		30.5%	<0.001		23.2%	<0.001
Explained variance		46.6%			54.3%	

Abbreviations: FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity.

Note: Bold numbers represent significant relationships.

At baseline, patients who reported pain scored higher on fatigue (M=2.9, SD=2.05) compared with patients who reported no pain (M=2.03, SD=1.8, t=3.28, p=0.001). Patients who reported pain at baseline also reported higher mean fatigue at five-month follow-up (M=3.54, SD=2.21) compared with those who reported no pain at baseline (M=2.55,

1
2
3 SD=2.04, $t=3.08$, $p=0.002$). Among the reported symptoms, coughing, depression, sleep
4 disturbance, and pain interference were related to preoperative fatigue after controlling for
5 age, sex, clinical variables, and the other symptoms. The total model explained 46.6% of
6 variance, while 30.5% was explained by the other symptoms.
7
8
9
10

11
12 At five-month follow-up, the only variables that predicted fatigue after controlling for
13 age, sex, clinical variables, preoperative fatigue, and symptoms were shortness of breath and
14 coughing. The total model explained 54.3% of variance, while 23.2% was explained by the
15 other symptoms.
16
17
18
19
20
21

22 **4. Discussion**

23
24
25 To our knowledge, this is the first study examining fatigue in surgically treated patients
26 with LC, including both preoperative data and data from five-month follow-up. Preoperative
27 fatigue was significantly correlated with comorbidities and all the included symptoms in the
28 bivariate analyses, while postoperative fatigue was significantly correlated with comorbidities
29 and four out of six measured symptoms. However, shortness of breath was the only baseline
30 variable that predicted postoperative fatigue.
31
32
33
34
35
36
37
38
39

40 *4.1. Relationship between postoperative fatigue level and preoperative symptoms*

41
42
43 Shortness of breath, coughing, depression, anxiety, sleep disturbance, and pain
44 interference were significantly correlated with level of preoperative fatigue. Except for
45 anxiety and pain interference, the same symptoms were associated with postoperative fatigue
46 in the bivariate analyses at five-month follow-up. Before surgery, cough was significantly
47 associated with fatigue, while shortness of breath was the symptom predictive of
48 postoperative fatigue. Shortness of breath is a prevalent and disturbing symptom in these
49 patients, which is physiologically based on disease location, damage caused by lung tumors,
50 and history of smoking. Shortness of breath requires intensive effort to breath, thus making
51
52
53
54
55
56
57
58
59
60

1
2
3 patients tired. The constant use of rib and respiratory muscles caused by shortness of breath
4
5 can exacerbate fatigue.[41] These patients may benefit from prescribed bronchodilators and
6
7 non-pharmacological treatment such as physical activity. For some, it may be useful to learn
8
9 how to manage shortness of breath by controlled breathing techniques and practicing calming
10
11 techniques during shortness of breath episodes.
12
13

14
15 Consistent with previous research, we found that fatigue in patients with LC undergoing
16
17 surgery is correlated with their symptoms and might cluster with other symptoms.[2,42]
18
19 Cheville et al.,[2] found a cluster of fatigue, cough, and dyspnea in LC survivors lasting for
20
21 eight years; however, in a later study, the same group found that the cluster did not predict
22
23 patient outcomes but that fatigue and dyspnea, alone and together, were sufficient to predict
24
25 important outcomes.[8]
26
27

28 29 *4.2. Relationship between fatigue and patients' disease characteristics and treatment* 30 31

32
33 Although comorbidities did not predict postoperative fatigue in our analyses, there was
34
35 a bivariate relationship with fatigue both pre- and postoperatively. Others have also reported
36
37 correlations between comorbidity and fatigue.[6,12] Respiratory comorbidities and cardiac
38
39 disease are especially related to fatigue in patients with LC.[3,43] We also found a correlation
40
41 between fatigue and spirometry results, with lower FEV1 and FVC related to higher levels of
42
43 fatigue at both measurement times. These variables were related to comorbidity and are an
44
45 important factor in identifying and screening patients at risk for developing fatigue. Poorer
46
47 respiratory test outcomes could indicate shortness of breath or respiratory comorbidities, such
48
49 as COPD, and may lead to distress and exhaustion and contribute to fatigue in these patients.
50
51

52
53 Surgery type has been established as a predictor of fatigue in LC survivors and surgery
54
55 has been associated with a greater symptom burden generally.[21] In the present study,
56
57 treatment and disease variables did not correlate with postoperative fatigue at five-month
58
59 follow-up. These findings are inconsistent with other reports in which correlations have been
60

1
2
3 found between fatigue and chemotherapy,[9] and radiotherapy.[11] However, our findings are
4
5 consistent with those from a general cancer population on the symptom cluster of pain,
6
7 fatigue, sleep disturbance, and depression. That group found that symptom experiences were
8
9 independent of demographic, disease, or treatment effects; their findings suggest that different
10
11 subgroups of patients may harbor different determinants (e.g., genetic) for experiencing
12
13 symptoms and suggested etiology that are independent of demographic, disease, or treatment
14
15 characteristics.[44]
16
17

18 19 20 *4.3. Limitations* 21

22
23 Some study limitations need to be acknowledged. There was a five-month gap between
24
25 the two measurement points. During this time, other factors might have influenced patients'
26
27 fatigue experience. Surgery type might also be a predictor of patient fatigue.[21] In this study,
28
29 only 6% of patients had video-assisted thoracoscopy; thus, it is not possible to determine
30
31 whether this influenced postoperative fatigue. Detailed information on symptom management
32
33 interventions such as physiotherapy and rehabilitation was not collected. However, even if
34
35 these variables had been included, no detailed information about the type and length of these
36
37 therapies was available.
38
39
40

41 42 **5. Conclusions** 43

44
45 Based on the findings in the present study, patients should be screened for symptoms
46
47 before surgery and offered treatment for their symptoms to reduce pre- and postoperative
48
49 fatigue. Special attention should be given to treating patients' shortness of breath, since this is
50
51 a modifiable predictor for which treatments are available. Further research should pay specific
52
53 attention to the pair of symptoms of shortness of breath and fatigue, and to the effects on
54
55 fatigue and QOL when shortness of breath is treated.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Fig. 1. Flowchart of the enrollment and exclusion of patients in the study.

For peer review only

Acknowledgements

We thank all of the patients who kindly participated and the nurses and physicians at Oslo University Hospital, St. Olav University Hospital, and Haukeland University Hospital who facilitated data collection.

Footnotes

Contributors: TR and TO conceptualised the study. TO wrote the protocol manuscript and TR contributed to protocol development. TO had responsibility for data collection. TH and AL conducted the data analyses and drafted the initial report. TO and TR critically reviewed and edited the manuscript. All authors read and approved the final manuscript. Each author contributed to interpreting the analyses and to critically revising the article, and approved the final draft.

Funding: The study was funded by the Norwegian Cancer Association.

Patient consent: Each participant signed informed consent.

Ethics approval The Regional Ethics Committee for the South-East 2010/1508, and the Institutional Review Boards (Personvernombudet) at each hospital approved the study. Each participant received written information about the study and signed informed consent.

Data availability statement: All data relevant to the study are included in the article.

Competing interests: None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

References

1 Kreftregisteret. Available from <https://www.kreftregisteret.no/en/General/Publications/Cancer-in-Norway/cancer-in-norway-2017/> (Accessed 10 May 2019).

1
2
3 2 Cheville AL, Novotny PJ, Sloan JA et al. Fatigue, dyspnea, and cough comprise a
4 persistent symptom cluster up to five years after diagnosis with lung cancer. *J Pain Symptom*
5 *Manag* 2011;42:202–212. doi:10.1016/j.jpainsymman.2010.10.257.

6
7 3 Hung R, Krebs P, Coups EJ, et al. Fatigue and functional impairment in early-stage non-
8 small cell lung cancer survivors. *J Pain Symptom Manag* 2011;41:426–435.
9 doi:10.1016/j.jpainsymman.2010.05.017.

10
11 4 Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and
12 Management. *Oncologist* 1991;4:1–10. doi:10.1097/01893697-200119020-00038.

13
14 5 Lee KA, Hicks G, Nino-Murcia G, Validity and reliability of a scale to assess fatigue.
15 *Psychiatry Res* 1990;36:291–298. doi:10.1016/0165-1781(91)90027.

16
17 6 Carnio S, Di Stefano RF, Novello S. Fatigue in lung cancer patients: symptom burden
18 and management of challenges. *Lung Cancer (Auct)* 2016;7:73–82. doi:
19 0.2147/LCTT.S85334.

20
21 7 Sarna L, Padilla G, Holmes C, et al. Quality of life of long-term survivors of non-small-cell
22 lung cancer. *J. Clin Oncol* 2002;20:2920–2929. doi:10.1200/JCO.2002.09.045.

23
24 8 Cheville AL, Novotny PJ, Sloan JA, et al. The value of a symptom cluster of fatigue,
25 dyspnea, and cough in predicting clinical outcomes in lung cancer survivors. *J Pain Symptom*
26 *Manag* 2011;42:213–221. doi:10.1016/j.jpainsymman.2010.11.005.

27
28 9 Long NH, Thanasilp S, Thato R. A causal model for fatigue in lung cancer patients
29 receiving chemotherapy. *Eur J Oncol Nurs* 2016;21:242-247.
30 doi:10.1016/j.ejon.2015.10.010.

31
32 10 Molassiotis A, Lowe M, Blackhall F, et al. A qualitative exploration of a respiratory distress
33 symptom cluster in lung cancer: cough, breathlessness and fatigue. *Lung Cancer*
34 2011;71:94–102. doi:10.1016/j.lungcan.2010.04.002.

35
36 11 Ozturk A, Sarihan S, Ercan I, et al. Evaluating quality of life and pulmonary function of
37 long-term survivors of non-small cell lung cancer treated with radical or postoperative
38 radiotherapy. *Am J Clin Oncol* 2009;32:65-72. doi:10.1097/COC.0b013e31817e6ec2.

39
40 12 Sarna L, Cooley ME, Brown JK, et al. Symptom severity 1 to 4 months after thoracotomy
41 for lung cancer. *Am J of Crit Care* 2008;17:455-467.

42
43 13 Poghosyan H, Sheldon LK, Leveille SG, et al. Health-related quality of life after surgical
44 treatment in patients with non-small cell lung cancer: a systematic review. *Lung Cancer*
45 2013;81:11-26. doi:10.1016/j.lungcan.2013.03.013.


46
47 14 Hoffman AJ, Given BA, von Eye A, et al. Relationships among pain, fatigue, insomnia,
48 and gender in persons with lung cancer. *Oncol Nurs Forum* 2007;34:785.
49 <http://ezproxy.diastud.no/docview/223105953?accountid=37793>.

50
51 15 Wright F, Melkus GDE, Hammer M, et al. Trajectories of evening fatigue in oncology
52 outpatients receiving chemotherapy. *J Pain Symptom Manag* 2015;50:163-175.
53 doi:10.1016/j.jpainsymman.2015.02.015.

54
55 16 Wright F, Melkus GDE, Hammer M, et al. Predictors and trajectories of morning fatigue
56 are distinct from evening fatigue. *J Pain Symptom Manag* 2015;50:176-189.
57 doi:10.1016/j.jpainsymman.2015.02.016

- 1
2
3
4 17 Storey DJ, Waters RA, Hibberd CJ, et al. Clinically relevant fatigue in cancer outpatients:
5 the Edinburgh Cancer Centre symptom study. *Ann Oncol* 2007;18:1861-1869.
6 doi:10.1093/annonc/mdm349.
7
- 8 18 Huang X, Zhou W, Zhang Y. Features of fatigue inpatients with early-stage non-small
9 cell lung cancer. *J Res Med Sci*; 2015;20:268–272.
10
- 11 19 Lerdal A, Wahl A, Rustøen T, Hanestad BR, Moum T. Fatigue in the general population: a
12 translation and test of the psychometric properties of the Norwegian version of the fatigue
13 severity scale. *Scand J Public Health* 2005;33:123-130. doi:10.1080/14034940410028406
14
- 15 20 Loge JH, Ekeberg Ø, Kaasa S. Fatigue in the general Norwegian population: Normative
16 data and associations. *J Psychosomatic Research* 1998;45:53-65. doi:10.1016/S0022-
17 3999(97)00291-2
18
- 19 21 Yang P, Chevillat AL, J.A. Wampfler JA, et al., Quality of life and symptom burden among
20 long term lung cancer survivors: changing and adapting, *J Thorac Oncol* 2012;7:64–70.
21 doi:10.1097/JTO.0b013e3182397b3e.
22
- 23 22 Oksholm T, Rustoen T, Cooper B, et al. Trajectories of symptom occurrence and severity
24 from before through five months after lung cancer surgery. *J Pain Symptom Manag*
25 2015;49:995–1015. doi:10.1016/j.jpainsymman.2014.11.297.
26
- 27 23 Oksholm T, Miaskowski C, Solberg S, et al., Changes in symptom occurrence and
28 severity before and after lung cancer surgery, *Cancer Nurs* 2015;38:351–357. doi:
29 10.1097/NCC.000000000000198.
30
- 31 24 Oksholm T, Miaskowski C, J.S. Kongerud JS, et al. Does age influence the symptom
32 experience of lung cancer patients prior to surgery? *Lung Cancer* 2013;82:156–161.
33 doi:10.1016/j.lungcan.2013.06.016.
34
- 35 25 Sangha O, Stucki G, Liang MH, et al. The Self-Administered Comorbidity Questionnaire: a
36 new method to assess comorbidity for clinical and health services research. *Arthrit Care Res*
37 2003;49:156–163. doi:10.1002/art.10993.
38
- 39 26 Miaskowski C, Lee KA. Pain, fatigue, and sleep disturbances in oncology outpatients
40 receiving radiation therapy for bone metastasis: a pilot study. *J Pain Symptom Manag*
41 1999;17:320–332. doi:10.1016/S0885-3924(99)00008-1.
42
- 43 27 Lerdal A, Kottorp A, Gay CL, et al. Lee Fatigue and Energy Scales: exploring
44 aspects of validity in a sample of women with HIV using an application of a Rasch model,
45 *Psychiatry Res* 2013;205;241–246. doi:10.1016/j.psychres.2012.08.031.
46
- 47 28 Bergman B, Aaronson N, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular
48 supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in
49 lung cancer clinical trials. *Eur J Cancer* 1994;30:635–642. doi:10.1016/0959
50 8049(94)90535-5.
51
- 52 29 Giesinger JM, Kieffer JM, Fayers PM, et al. Replication and validation of higher order
53 models demonstrated that a summary score for the EORTC QLQ-C30 is robust. *J Clin*
54 *Epidemiol* 2016;69:79–88. doi:10.1016/j.jclinepi.2015.08.007.
55
- 56 30 Michelson H, Bolund C, Nilsson B, et al. Health-related quality of life
57 measured by the EORTC QLQ-C30: reference values from a large sample of the Swedish
58
59
60

- 1
2
3 population. *Acta Oncol* 2000;39:477–484. doi:10.1080/028418600750013384
4
5 31 Radloff LS. The CES-D scale: a self-report depression scale for the general population,
6 *Appl Psych Mea*. 1977;1:385–401. doi:10.1177/014662167700100306.
7
8 32 Sheehan JT, Fifield J, Reisine S, et al. The measurement structure of the Center
9 for Epidemiologic Studies Depression Scale. *J Pers Assess* 1995;64:507-521.
10 doi:10.1207/s15327752jpa6403_9.
11
12 33 Spielberger CD, Gorsuch RC, Lushene RE, et al. Manual for the
13 State-Trait Anxiety Inventory (Form Y): Self-Evaluation Questionnaire. Consulting
14 Psychologists Press, Palo Alto, CA, 1983.
15
16 34 Cataldo JK, Brodsky JL. Lung cancer stigma, anxiety, depression and symptom
17 Severity. *Oncology* 2013;85:33–40. doi:10.1159/000350834.
18
19 35 Lee KA. Self-reported sleep disturbances in employed women. *Sleep* 1992;15:493-
20 498. doi:10.1093/sleep/15.6.493.
21
22 36 Cleeland CS, Measurement and prevalence of pain in cancer. *Seminars in Onc Nurs*
23 1985;1:87–92. doi: 10.1016/S0749-2081(85)80041-3.
24
25 37 Klepstad P, Loge JH, Borchgrevink PC, et al. The Norwegian Brief Pain Inventory
26 Questionnaire: translation and validation in cancer pain patients. *J Pain Symptom Manag*
27 2002;24: 517–525. doi /10.1016/S0885-3924(02)00526-2.
28
29 38 von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational
30 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
31 *BMJ* 2007;335:806-8.
32
33 39 Cohen J. A power primer: quantitative methods in psychology. *Psychological Bulletin*
34 1992;112;155-159. doi:10.1037/0033-2909.112.1.155
35
36 40 Soper DS. Post-hoc statistical power calculator for hierarchical multiple regression
37 (Software) 2017. Available from: <http://www.danielsoper.com/statcalc/references.aspx?id=17>
38 (Accessed 10 May 2019).
39
40 41 Esper P, Heidrich D, Symptom clusters in advanced illness. *Seminars in Oncology*
41 *Nursing* 2005;25:20–28. doi:10.1053/j.soncn.2004.10.004.
42
43 42 Lin S, Chen Y, Yang L, et al. Pain, fatigue, disturbed sleep and distress comprised a
44 symptom cluster that related to quality of life and functional status of lung cancer surgery
45 patients. *J Clinical Nurs* 2013; 22.9-10:1281–1289. doi:10.1111/jocn.12228.
46
47 43 Yun YH, Kim YA, Min YH, et al., Health-related quality of life in disease-free survivors of
48 surgically treated lung cancer compared with the general population, *Ann Surg*
49 2012;255:1000–1007. doi:10.1097/SLA.0b013e31824f1e9e.
50
51 44 Miaskowski C, Cooper BA, Paul SM, et al. Subgroups of patients with cancer with
52 different symptom experiences and quality-of-life outcomes: a cluster analysis. *Oncol Nurs*
53 *Forum* 2006;33.
54
55
56
57
58
59
60



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Page: 1 and 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page: 2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page: 3 and 4
Objectives	3	State specific objectives, including any prespecified hypotheses Page: 4
Methods		
Study design	4	Present key elements of study design early in the paper Page: 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page: 5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Page: 5 and 6
		(b) For matched studies, give matching criteria and number of exposed and unexposed Page: Not actual
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page: 5-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page: 5-8
Bias	9	Describe any efforts to address potential sources of bias Page: Not actual
Study size	10	Explain how the study size was arrived at Page: 10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page:
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page: 9
		(b) Describe any methods used to examine subgroups and interactions Page: 9
		(c) Explain how missing data were addressed Page: 9
		(d) If applicable, explain how loss to follow-up was addressed Page: 9
		(e) Describe any sensitivity analyses Page: 9

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page: Fig 1, page 10
		(b) Give reasons for non-participation at each stage Page: Fig 1, page 10
		(c) Consider use of a flow diagram Page: Fig 1, page 10
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page: 11
		(b) Indicate number of participants with missing data for each variable of interest Page: 11
		(c) Summarise follow-up time (eg, average and total amount) Page: 11
Outcome data	15*	Report numbers of outcome events or summary measures over time Page: 10 -12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Page: 12
		(b) Report category boundaries when continuous variables were categorized Page: 12
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Page: Not actual
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Page: Not actual
Discussion		
Key results	18	Summarise key results with reference to study objectives Page: 14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page: 2 + 16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page: 15 and 16
Generalisability	21	Discuss the generalisability (external validity) of the study results Page: 16
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page: 18

*Give information separately for exposed and unexposed groups.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

For peer review only

BMJ Open

Predicting postoperative fatigue in surgically treated lung cancer patients in Norway– a longitudinal five-month follow-up study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028192.R2
Article Type:	Original research
Date Submitted by the Author:	26-Aug-2019
Complete List of Authors:	Hugoy, Therese ; University of Oslo, Institute of Health and Society, Faculty of Medicine, ; Lovisenberg Diakonale Hogskole Lerdal, Anners; University of Oslo, Dept. of Interdisciplinary Health Sciences, Institute of Health and Society; Lovisenberg Diakonale Hospital, Dept. of Research Rustoen, Tone; University of Oslo, Norway, Institute of Health and Society, Faculty of Medicine; Oslo universitetssykehus Ulleval, Department of Research and Development, Division of Emergencies and Critical Care Oksholm, Trine; VID Vitenskapelige Hogskole, Faculty of Health Studies, Campus Haraldsplass
Primary Subject Heading:	Nursing
Secondary Subject Heading:	Oncology, Surgery
Keywords:	Fatigue, Lung Cancer, Neoplasm, Quality of Life, SURGERY

SCHOLARONE™
Manuscripts

1
2
3 **Predicting postoperative fatigue in surgically treated lung cancer patients in Norway– a**
4 **longitudinal five-month follow-up study.**
5
6

7 Therese Hugøy^{a,b,c}, Anners Lerdal^{d,e} Tone Rustøen^{a,f}, Trine Oksholm^g
8
9

10
11 ^aDepartment of Nursing Science, Institute of Health and Society, Faculty of Medicine,
12 University of Oslo, Norway.
13

14 ^bCentre for Patient centered heart- and lung research. Department of cardiothoracic surgery.
15 Division of Cardiovascular and Pulmonary Diseases. Oslo University Hospital, Oslo, Norway.
16
17

18 ^cLovisenberg Diaconal University College, Lovisenberggt. 15B, 0456 Oslo, Norway
19

20 ^dDept. of Interdisciplinary Health Sciences, Institute of Health and Society, Faculty of
21 Medicine
22

23 ^eDepartment for Patient Safety and Research, Lovisenberg Diaconal Hospital, P.O. Box 4970
24 Nydalen,0440 Oslo, Norway
25
26

27 ^f Department of Research and Development, Division of Emergencies and Critical Care, Oslo
28 University Hospital, P.O. Box 4956 Nydalen, 0424 Oslo, Norway;
29

30 ^g VID Specialized University, Faculty of Health Studies, Campus Haraldsplass, P.O. Box 184
31 Vinderen, 0319 Oslo, Norway
32
33

34
35
36 *Corresponding author at:
37 Trine Oksholm
38 trine.oksholm@vid.no
39
40

41
42
43
44 Word count: 3275
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Despite the negative influence of fatigue on quality of life in patients who undergo lung cancer surgery, little is known about the possible predictors of postoperative fatigue. The aim of this study was to examine demographic and clinical characteristics that might predict postoperative fatigue five months after lung cancer surgery.

Design: A prospective longitudinal follow up study comprising pre- and postoperative questionnaires, including Lee Fatigue Scale, and sociodemographic and clinical data.

Setting: Three university hospitals in Norway (e.g., Oslo University Hospital, St. Olav University Hospital, Haukeland University Hospital).

Participants: In total, 196 surgically treated patients who answered the questionnaires both preoperatively and at five-month follow-up with valid fatigue scores.

Results: Bivariate analyses showed that preoperative fatigue was associated with comorbidities and the symptoms of shortness of breath, cough, depression, anxiety, sleep disturbance, and pain. Only cough was directly associated with preoperative fatigue in a regression model. Comorbidities and the symptoms of shortness of breath, cough, depression, and sleep disturbance were associated with postoperative fatigue in the bivariate analyses, but only shortness of breath was associated with postoperative fatigue in the regression model. We did not find any significant correlations between fatigue and any treatment variable.

Conclusion: Clinicians should pay special attention to lung symptoms and be aware that these may lead to long-term postoperative fatigue. Further research should examine whether interventions reducing lung symptoms, such as shortness of breath and coughing, may prevent development of fatigue in patients undergoing lung cancer surgery.

Key words: Fatigue, Lung Cancer, Neoplasm, Quality of Life, Surgery

Strengths and limitations of this study

- Fatigue is a symptom that has a great impact on patients quality of life and this topic is relevant both to patients and healthcare providers
- A rather large sample of surgically treated lung cancer patients were included in the study patients', fatigue was measured both preoperatively and after surgery. This gives information about fatigue after lung cancer surgery.
- There was a five-month gap between the two measurement points. During this time, other factors might have influenced patients' fatigue experience.
- There were limited information on symptom management interventions such as physiotherapy and rehabilitation

1. Introduction

Lung cancer (LC) is presently one of the most common malignancies, and it is estimated that 20% of cancer-related deaths are caused by LC.[1] Only 20% of patients diagnosed with non-small-cell lung cancer meet the criteria for surgery due to their late stage at diagnosis; for these patients, surgery may be curative.[2] In Norway during 2014, five-year LC survival was generally 19% in women and 13% in men.[1] In surgically treated patients, the five-year survival ranges from 50% to 70%, depending on the tumor stage at surgery.

Fatigue is common among cancer patients. An estimated 75–90% of patients with LC report fatigue after cancer treatment.[3,4] Fatigue has been described as a complex, multidimensional symptom and has been defined as a sense of exhaustion, lack of energy, or tiredness distinct from sleepiness, sadness, or weakness.[5] Cancer-related fatigue is related to cancer or its treatment, and interferes with usual functioning.[3] Fatigue has a negative impact on patients' health-related quality of life (HRQOL),[6] their ability to receive treatment, and their long-term prognosis. Although there are limited data on LC and fatigue in patients who have undergone surgery, it has been shown that fatigue has a negative impact on HRQOL in

1
2
3 LC survivors.[7] One study showed that fatigue was a significant predictor of survival at each
4 time point assessed.[8] In another study on symptom severity after thoracotomy, fatigue was
5 reported as the most common and severe symptom at every time point.[7]
6
7
8
9

10 Several studies have reported interrelations between fatigue, cough, and dyspnea.[8–11]
11 Fatigue is also strongly related to symptoms of depression and anxiety.[12,13] Associations
12 between fatigue and sex, pain, insomnia, and dyspnea have also been reported.[12,14] Studies
13 on fatigue in populations with lung cancer in different stages have also shown strong
14 correlations between fatigue and sleep disturbance.[6,15–17] Sarna et al.,[12] found that
15 symptom severity in surgical patients was related to the extent of their comorbid condition.
16 Other studies of patients with LC have also shown correlations between comorbidities and
17 fatigue,[6] as well as strong correlations between pulmonary diseases such as COPD and
18 asthma, and fatigue.[3,18] Studies of fatigue in the general population has shown a higher
19 proportion of severe fatigue cases among women than among men.[19,20] Thus, examining
20 differences in fatigue in relation to sex among LC patients is of interest. Fatigue has a
21 negative impact on both patients with LC and survivors in general;[21] however, to our
22 knowledge, there have been no studies to date specifically investigating fatigue in surgically
23 treated patients with LC.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Thus, our aim was to examine the relationships between fatigue and disease
43 characteristics, treatment, and other symptoms. We hypothesized that fatigue levels at five-
44 month follow-up would be significantly related to: (1) sex, (2) clinical variables (preoperative
45 comorbidities, forced expiratory volume in one second [FEV1], and forced vital capacity
46 [FVC]); (3) preoperative symptoms (shortness of breath, coughing, depression, anxiety, pain,
47 and sleep disturbance); and (4) treatment and medical variables (surgery type, cancer stage,
48 and adjuvant therapy).
49
50
51
52
53
54
55
56
57
58
59

60 **2. Material and methods**

1
2
3 This study is part of a larger, longitudinal investigation of symptoms in patients with LC
4 who were eligible for surgery,[22–24] for which data were collected prior to surgery and
5 prospectively at four time points up to one year after surgery. Here, we analyzed the data
6 collected prior to surgery and at the five-month follow-up to gain insight into patients'
7 experiences with fatigue before surgery and after the immediate postoperative period.
8
9
10
11
12
13
14

15 16 *2.1. Patients and settings*

17
18 Patients were included if they were 18 years or older, scheduled for primary LC surgery,
19 and could understand, read, and write Norwegian. Patients with a benign or metastatic
20 disease, whose surgery was canceled, or who had cognitive impairment, were excluded. We
21 recruited patients from three university hospitals in Norway: Oslo University Hospital, St.
22 Olav University Hospital, and Haukeland University Hospital. The recruitment started in
23 November 2010 and was completed in March 2012.
24
25
26
27
28
29
30
31
32
33

34 35 *2.2 Patient and Public Involvement*

36
37 The study was funded Norwegian Cancer Society (NCS). The study was discussed with
38 representatives from the Lung Cancer subgroup before the study started and an article about
39 the main result from the study is published in the membership journal for patients with lung
40 cancer.
41
42
43
44
45
46

47 48 *2.3. Study procedures*

49
50 Hospital research staff approached patients and explained the study purpose: 91% of the
51 participants were recruited in the hospital 1–3 days before surgery, and the remainder in
52 outpatient clinics prior to surgery. Patients signed a written informed consent before they
53 completed several self-report questionnaires with information on sociodemographic and
54 clinical characteristics, and symptoms both prior to surgery and at a five-month follow-up.
55
56
57
58
59
60

1
2
3 Permission to use the questionnaire was obtained from the copyright detectors before study
4 start. Data on type of tumor, cancer stage, surgery type, and lung function were collected from
5 the patients' medical records. FEV1 and FVC were measured preoperatively using a
6 spirometer. Five months after surgery, patients received questionnaires by regular mail, along
7 with a postage-paid return envelope.
8
9

10 11 12 13 14 15 16 *2.4. Instruments and assessment*

17 18 19 *2.4.1. Sociodemographic, clinical, symptom, and fatigue characteristics*

20
21 Patients provided information on their sex, marital status, living situation, level of
22 education, and employment status. Information on age, smoking status, FEV1, tumor
23 histology, cancer stage, type of surgery, pre- and postoperative treatment, postoperative
24 complications, and TNM classification were collected from patients' medical records; the
25 TNM classification is a system for cancer staging based on tumor (T), node (N), and
26 metastasis (M).
27
28
29
30
31
32
33
34

35 36 *2.4.2. Comorbidities*

37
38 Comorbidities were measured using the Self-administered Comorbidity Questionnaire-
39 19 (SCQ-19),[25] on which scores can range from 0 to 57, with a higher score indicating a
40 more severe comorbidity profile. The SCQ includes 16 comorbidities and three optional
41 conditions. Patients indicated whether or not they had the comorbid condition (yes/no); if they
42 had the condition they were asked if they received treatment for it; and finally if it limited
43 their activities. The SCQ-19 has well-established validity and reliability and has been used to
44 assess comorbidity in Norwegian oncology patients.[25] Only the number of comorbidities
45 was used in the present study.
46
47
48
49
50
51
52
53
54

55 56 57 *2.4.3. Fatigue*

1
2
3 The Lee Fatigue Scale (LFS),[5] was used to measure fatigue at baseline and five-month
4 follow-up. The LFS consists of 18 items designed to assess fatigue (13 items) and energy (5
5 items). We used only the 13 fatigue items in this study. Patients were asked to rate each item
6 on a 0–10 scale, with a higher score indicating greater fatigue severity. A fatigue score was
7 calculated using the mean of the 13 items at each measurement. The LFS has well-established
8 validity and reliability.[26,27] Fatigue scores at baseline were defined as preoperative fatigue
9 and at five-month follow-up as postoperative fatigue.
10
11
12
13
14
15
16
17
18

19 2.4.4. *Shortness of breath and cough*

20
21 The European Organization for Research and Treatment of Cancer Quality-of-Life
22 Questionnaire – Lung Cancer Module (EORTC QLQ-LC13),[28] was used to measure
23 shortness of breath and cough. Patients were asked to rate their severity on each shortness of
24 breath and cough item using a four-point Likert scale where 1 = not at all; 2 = a little; 3 =
25 quite a bit; and 4 = very much. The EORTC QLQ-LC13 has been validated in Norwegian LC
26 patients.[29,30]
27
28
29
30
31
32
33
34

35 2.4.5. *Depression*

36
37 The Center for Epidemiologic Studies – Depression Scale (CES-D),[31] was used to
38 measure depression symptoms. The scale has 20 items related to depression and patients were
39 asked to report how they felt during the past week. Each item was rated on a four-point Likert
40 scale and scores ranged from 0 to 60, with a higher score indicating a higher level of
41 depression. A total depression score was calculated as the mean of all the sub scores.
42 Acceptable reliability and validity have been reported in a previous study.[32]
43
44
45
46
47
48
49
50
51

52 2.4.6. *Anxiety*

53
54 The State-Trait Anxiety Inventory (STAI, Y-2),[33] was used to measure anxiety. The
55 STAI includes 20 items related to anxiety rated on a four-point Likert scale. Scores range
56
57
58
59
60

1
2
3 from 20 to 80, with a higher score indicating a higher level of anxiety. The STAI has been
4
5 validated in patients with LC.[34]
6
7

8 *2.4.7. Sleep disturbance*

10 The General Sleep Disturbance Scale (GSDS),[35] was used to measure sleep
11
12 disturbance. The GSDS consists of 21 items related to sleep disturbance. Each item is rated on
13
14 a numeric rating scale ranging from 0 (never) to 7 (every day). A sleep disturbance score was
15
16 calculated from the mean of all scale items. Higher scores indicate more severe sleep
17
18 disturbance. The GSDS has been validated in cancer patients.[26]
19
20
21

22 *2.4.8. Pain*

24 The Brief-Pain Inventory (BPI),[36] was used to measure pain interference. The BPI is
25
26 a multidimensional questionnaire measuring pain intensity (four items), pain interference
27
28 (seven items), pain relief (one item), and pain location (body map). Only pain interference
29
30 was used in the present study. The seven interference items (general activity, normal work,
31
32 walking ability, mood, relationships with other people, sleep, and enjoyment of life) were
33
34 combined into a single interference item. The measurement scale ranges from 0 to 10, with
35
36 higher scores indicating more pain interfering with daily living. The BPI has been validated in
37
38 Norwegian cancer patients.[37]
39
40
41
42
43

44 *2.5. Ethics*

46 The Regional Ethics Committee for the South-East 2010/1508, and the Institutional Review
47
48 Boards (Personvernombudet) at each hospital approved the study. Each participant received
49
50 written information about the study and signed informed consent. The article complies with
51
52 the STROBE guidelines.[38]
53
54
55
56

57 *2.6. Statistical analyses*

1
2
3 Descriptive statistics were used to describe the sociodemographic, clinical, and
4
5 treatment characteristics of the patient sample. Differences between sexes were analyzed
6
7 using a chi-squared test for categorical variables and an independent Student's *t* test for the
8
9 continuous variables. One-way ANOVA was used to explore differences within groups on
10
11 levels of pre- and postoperative fatigue. Patients with more than 20% of missing items on the
12
13 LFS were excluded from analyses. If the scales had less than 20% missing, the score were
14
15 calculated from the mean of the particular patient's valid scores. The bivariate relationships
16
17 between symptoms and fatigue at baseline were assessed using Pearson correlation analyses.
18
19 Variables with significant correlation coefficients on bivariate analyses were included in a
20
21 hierarchical linear analyses.
22
23
24
25

26 Two stepwise multivariate regression analyses were performed. In the first analysis,
27
28 preoperative fatigue was the dependent variable. In the second analysis, postoperative fatigue
29
30 was the dependent variable. In both analyses, age and sex were entered in step one. Clinical
31
32 variables including comorbidities, FEV1, and FVC were entered in step two. Finally, the
33
34 symptom variables of shortness of breath, cough, depression, anxiety, sleep disturbance, and
35
36 pain interference were entered in step three. For the second regression analysis, the model
37
38 also included a fourth step in which preoperative fatigue was included as an independent
39
40 variable.
41
42
43
44

45 The entry of variables in different model steps was carried out according to theoretical
46
47 and logical considerations. For all analyses, $p < 0.05$ was considered statistically significant.
48
49 Post hoc statistical power was calculated for hierarchical multiple regression: with an effect
50
51 size (f^2) for set B (five-month follow-up) at 0.15 (medium), [39] 11 predictors in set A and 12
52
53 in set B, a probability level of 0.05, and a sample size of 196, the observed power for the
54
55 addition of set B was 0.95. [40] Data were analyzed using SPSS (IBM Corporation, Armonk,
56
57 NY, USA) version 24.0.
58
59
60

Table 1

Demographic, clinical, and treatment characteristics of the patients (N=196).

	Total	Men	Women	Statistics	p-value
Sociodemographics					
Age in years (mean, SD)	196	66.7 (8.2)	64.1 (7.9)	t 2.28 (194)	0.024
		% (n)	% (n)	χ (df)	
Cohabitation (living with someone)	147	84.0 (89)	(69.0) 58	5.95 (1)	0.015
Work status					
Full or part time	58	27.6 (29)	34.9 (29)	.80 (2)	0.25
Sick leave or disability	47	22.9 (24)	27.7 (23)		
Retired	83	49.5 (52)	37.3 (31)		
Education					
≤12 years	158	81.1(86)	86.7 (72)	1.07 (1)	0.30
≥13 years	31	18.9 (20)	13.3 (11)		
Clinical variables					
		Mean (SD)	Mean (SD)	t (df)	
Comorbidities (SCQ)	193	3.72 (3.3)	4.67 (4.0)	-1.74 (161.4)	0.08
FEV1 (expected %)	190	76.7 (19.2)	80.4 (22.8)	-1.20 (188)	0.23
FVC (expected %)	183	91.2 (15.00)	102.4 (19.4)	t -4.30(149.8)	<.001
Symptoms					
Fatigue (LFS) baseline	196	2.50 (2.0)	2.48 (2.0)	t -0.07 (194)	0.94
Fatigue (LFS) 5-month follow-up					

3. Results

3.1. Sample characteristics

Totally, 375 patients with presumptive primary lung cancer were asked to participate in the study and 307 agreed to participate (Fig 1). Among these, 196 patients who answered the questionnaire both preoperatively and at five-month follow-up and had valid fatigue scores at both measurement points were included in the study. Sample characteristics are shown in Table 1. Although women were younger, more women lived alone, reported higher FVC, less shortness of breath and had a higher proportion of adenocarcinoma cancer type, and was more active in physiotherapy and rehabilitation than men, their level of fatigue did not differ. Most of the sample had adenocarcinoma stage 1A or 1B, received no preoperative treatment and had a lobectomy.

The mean preoperative fatigue scores were 2.49 (SD=2.02) for men and 2.47 (SD=1.96) for women. At the five-month follow-up, the postoperative fatigue scores were 3.0 (SD=2.1) for men and 2.9 (SD=2.1) for women. There were no significant differences in fatigue level preoperatively between those who completed or did not complete the postoperative fatigue scale.

1						
2						
3		196	3.0 (2.2)	2.9 (2.1)	t 0.32 (194)	0.75
4	Shortness of breath					
5	(EORTC)	194	2.24 (0.8)	2.00 (0.7)	t -2.28 (192)	0.023
6	Cough (EORTC)	193	1.96 (0.7)	1.98 (0.8)	t -0.11 (191)	0.92
7	Depression (CES-D)	190	10.49 (8.8)	12.92 (8.8)	t -1.89 (188)	0.06
8	Anxiety (STAI)	192	51.22 (3.1)	50.80 (2.9)	t 0.96 (190)	0.34
9	Sleep disturbance (GSDS)	191	2.26 (1.05)	2.32 (1.00)	t -0.36 (189)	0.72
10			% (n)	% (n)	χ (df)	p-value
11	Pain (BPI) yes	171	40.0 (38)	51.3 (39)	2.18 (1)	0.14
12	Pathology and treatment					
13	Tumor type					
14	Adenocarcinoma	106	45.0 (50)	65.9 (56)	24.00 (4)	<.001
15	Squamous cell	66	45.0 (50)	12.9 (11)		
16	Small cell	5	1.8 (2)	3.5 (3)		
17	Carcinoid	6	1.8 (2)	4.7 (4)		
18	Other	18	6.3 (7)	12.9 (11)		
19	Stage of cancer disease					
20	IA	58	25.2 (27)	41.3 (31)	9.12 (4)	0.06
21	IB	59	35.5 (38)	28.0 (21)		
22	II	35	24.3 (26)	12.0 (9)		
23	IIIA	31	14.0 (15)	18.7 (14)		
24	IIIB-IV	1	0.9 (1)	-		
25	Preoperative treatment					
26	None	192	97.3 (108)	98.8 (84)	1.58 (3)	0.66
27	Radiation	1	0.9 (1)	-		
28	Chemotherapy	1	0.9 (1)	-		
29	Combination	2	0.9 (1)	1.2 (1)		
30	Type of surgery					
31	Lobectomy	133	67.6 (75)	68.2 (58)	1.26 (4)	0.87
32	Bilobectomy	15	6.3 (7)	9.4 (8)		
33	Pneumonectomy	18	9.0 (10)	9.4 (8)		
34	Wedge resection	18	9.9 (11)	8.2 (7)		
35	Thoracoscopic	12	7.2 (8)	4.7 (4)		
36	Postoperative complications					
37	Reoperation	9	3.6 (4)	5.9 (5)	0.57 (1)	0.45
38	Pneumonia	50	27 (30)	23.8 (20)	0.26 (1)	0.61
39	Posttreatment					
40	Radiation therapy	16	9.9 (11)	5.9 (5)	1.04 (1)	0.31
41	Chemotherapy	57	30.6 (34)	27.1 (23)	0.30 (1)	0.59
42	Physiotherapy	58	24.3 (26)	38.1 (32)	4.24 (1)	0.04
43	Rehabilitation	24	7.5 (8)	19.3 (16)	5.90 (1)	0.015

Abbreviations: SCQ, Self-administered Comorbidity Questionnaire; FEV1, forced expiratory volume in one second; FVC, Forced vital Capacity; EORTC, European Organization for Research and Treatment of Cancer; CES-D, Center for Epidemiologic Studies – Depression Scale; STAI, State-Trait Anxiety Inventory; GSDS, General Sleep Disturbance Scale; BPI, Brief Pain Inventory; LFS, Lee Fatigue Inventory.

Notes: Fatigue, range 0–10, higher score indicating greater fatigue severity; shortness of breath and cough range 1–4, higher score indicating more shortness of breath and cough; depression, range 0–60, higher score indicating more depression; pain, range 0–10, higher score indicating more pain; comorbidity, range 0–57, higher score indicating more comorbidity; anxiety, range 20–80, higher score indicating more anxiety; sleep disturbance, range 0–7, higher score indicating more severe sleep disturbance.

Bold numbers represent significant relationships.

3.2. Bivariate analyses

The bivariate analyses between the symptom variables are shown in Table 2. Medical and treatment characteristics including cancer stage, tumor type, type of surgery, and postoperative treatment such as radiation therapy, chemotherapy, physiotherapy, and rehabilitation were not significantly correlated with either preoperative or postoperative fatigue and, thus, were not included in the final model. Sociodemographic variables including

work, education, and cohabitation were excluded before the final analyses for the same reason.

Table 2

Correlation matrix for symptoms at baseline, and fatigue baseline and 5-month follow-up (N=196).

	1	2	3	4	5	6	7	8	9	10	11	12	13
1 Age	1												
2 Sex	-.16*	1											
3 FEV1	.06	.09	1										
4 FVC	.02	.31*	.65*	1									
5 Fatigue (LFS) baseline	-.23*	-.01	-.19*	-.14	1								
6 Fatigue (LFS) 5-month follow-up	-.16*	-.02	-.22*	-.17*	.52*	1							
7 Comorbidities (SCQ)	.04	.13	-.23*	-.12	.29*	.31*	1						
8 Shortness of breath (EORTC)	-.03	-.16*	-.25*	-.24*	.35*	.62*	.31*	1					
9 Cough (EORTC)	-.04	.01	-.14	-.15*	.33*	.33*	-.04	.17*	1				
10 Depression (CES-D)	-.15*	.14	-.07	-.03	.47*	.31*	.17*	.17*	.12	1			
11 Anxiety (STAI)	.06	-.07	.08	-.00	-.24*	-.12	-.08	-.01	-.1	-.28*	1		
12 Sleep disturbance (GSDS)	-.22*	.03	-.09	-.08	.50*	.41*	.18*	.26*	.14	.57*	-.22*	1	
13 Pain (BPI)	.1	-.11	.09	.1	-.25*	-.23*	-.18*	-.15	-.02	-.08	.18*	-.23*	1

* Correlation is significant at the 0.05 level (2-tailed).

Abbreviations: SCQ, Self-administered Comorbidity Questionnaire; FEV1, Forced expiratory volume in one second; FVC, Forced vital Capacity; EORTC, European Organization for Research and Treatment of Cancer; CES-D, Center for Epidemiologic Studies – Depression Scale; STAI, State-Trait Anxiety Inventory; GSDS, General Sleep Disturbance Scale; BPI, Brief Pain Inventory; LFS, Lee Fatigue Inventory.

3.3. Multivariate analyses

Hierarchical multiple regression analyses were used to assess the impact of the selected variables on levels of preoperative and postoperative fatigue (Table 3). Age, sex, and clinical variables were unrelated to preoperative fatigue.

Table 3

Results from the two hierarchical multivariate linear regression analyses with preoperative fatigue and postoperative fatigue (at 5-month follow-up) were used as dependent variables (N=196).

	Preoperative fatigue			Postoperative fatigue		
	Beta	β	p-value	Beta	β	p-value
Sociodemographics						
Age	-0.04	-0.14	0.13	-0.02	-0.07	0.26
Sex	-0.39	-0.10	0.16	0.03	0.01	0.93
Explained variance (R^2)		5.5%	0.01		2.9%	0.10
Clinical variables						
FEV1	-0.00	-0.05	0.63	-0.00	-0.03	0.71
FVC	-0.01	0.04	0.61	0.00	0.04	0.65
Comorbidity	0.10	0.18	0.008	0.05	0.08	0.19
R^2 change		10.6%	<0.001		12.1%	<0.001
Explained variance		16.1			15.0	
Fatigue at baseline						
Fatigue				0.18	0.17	0.03
R^2 change					16.2%	<0.001
Explained variance					31.2%	
Other symptoms at baseline						
Shortness of breath	0.33	0.13	0.06	1.27	0.46	<0.001
Cough	0.64	0.25	<0.001	0.50	0.18	0.004
Depression	0.05	0.23	0.003	0.01	0.04	0.63
Anxiety	-0.05	-0.07	0.29	0.00	0.00	0.95
Sleep disturbance	0.02	0.20	0.01	0.01	0.11	0.12
Pain	0.44	0.20	0.01	-0.29	-0.07	0.26
R^2 change		30.5%	<0.001		23.2%	<0.001
Explained variance		46.6%			54.3%	

Abbreviations: FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity.

Note: Bold numbers represent significant relationships.

At baseline, patients who reported pain scored higher on fatigue (M=2.9, SD=2.05) compared with patients who reported no pain (M=2.03, SD=1.8, t=3.28, p=0.001). Patients who reported pain at baseline also reported higher mean fatigue at five-month follow-up (M=3.54, SD=2.21) compared with those who reported no pain at baseline (M=2.55,

1
2
3 SD=2.04, $t=3.08$, $p=0.002$). Among the reported symptoms, coughing, depression, sleep
4 disturbance, and pain interference were related to preoperative fatigue after controlling for
5 age, sex, clinical variables, and the other symptoms. The total model explained 46.6% of
6 variance, while 30.5% was explained by the other symptoms.
7
8
9
10

11
12 At five-month follow-up, the only variables that predicted fatigue after controlling for
13 age, sex, clinical variables, preoperative fatigue, and symptoms were shortness of breath and
14 coughing. The total model explained 54.3% of variance, while 23.2% was explained by the
15 other symptoms.
16
17
18
19
20
21

22 **4. Discussion**

23
24
25 To our knowledge, this is the first study examining fatigue in surgically treated patients
26 with LC , including both preoperative data and data from five-month follow-up. Preoperative
27 fatigue was significantly correlated with comorbidities and all the included symptoms in the
28 bivariate analyses, while postoperative fatigue was significantly correlated with comorbidities
29 and four out of six measured symptoms. However, shortness of breath was the only baseline
30 variable that predicted postoperative fatigue.
31
32
33
34
35
36
37
38
39

40 *4.1. Relationship between postoperative fatigue level and preoperative symptoms*

41
42
43 Shortness of breath, coughing, depression, anxiety, sleep disturbance, and pain
44 interference were significantly correlated with level of preoperative fatigue. Except for
45 anxiety and pain interference, the same symptoms were associated with postoperative fatigue
46 in the bivariate analyses at five-month follow-up. Before surgery, cough was significantly
47 associated with fatigue, while shortness of breath was the symptom predictive of
48 postoperative fatigue. Shortness of breath is a prevalent and disturbing symptom in these
49 patients, which is physiologically based on disease location, damage caused by lung tumors,
50 and history of smoking. Shortness of breath requires intensive effort to breath, thus making
51
52
53
54
55
56
57
58
59
60

1
2
3 patients tired. The constant use of rib and respiratory muscles caused by shortness of breath
4
5 can exacerbate fatigue.[41] These patients may benefit from prescribed bronchodilators and
6
7 non-pharmacological treatment such as physical activity. For some, it may be useful to learn
8
9 how to manage shortness of breath by controlled breathing techniques and practicing calming
10
11 techniques during shortness of breath episodes.
12
13

14
15 Consistent with previous research, we found that fatigue in patients with LC undergoing
16
17 surgery is correlated with their symptoms and might cluster with other symptoms.[2,42]
18
19 Cheville et al.,[2] found a cluster of fatigue, cough, and dyspnea in LC survivors lasting for
20
21 eight years; however, in a later study, the same group found that the cluster did not predict
22
23 patient outcomes but that fatigue and dyspnea, alone and together, were sufficient to predict
24
25 important outcomes.[8]
26
27

28 29 *4.2. Relationship between fatigue and patients' disease characteristics and treatment* 30 31

32
33 Although comorbidities did not predict postoperative fatigue in our analyses, there was
34
35 a bivariate relationship with fatigue both pre- and postoperatively. Others have also reported
36
37 correlations between comorbidity and fatigue.[6,12] Respiratory comorbidities and cardiac
38
39 disease are especially related to fatigue in patients with LC.[3,43] We also found a correlation
40
41 between fatigue and spirometry results, with lower FEV1 and FVC related to higher levels of
42
43 fatigue at both measurement times. These variables were related to comorbidity and are an
44
45 important factor in identifying and screening patients at risk for developing fatigue. Poorer
46
47 respiratory test outcomes could indicate shortness of breath or respiratory comorbidities, such
48
49 as COPD, and may lead to distress and exhaustion and contribute to fatigue in these patients.
50
51

52
53 Surgery type has been established as a predictor of fatigue in LC survivors and surgery
54
55 has been associated with a greater symptom burden generally.[21] In the present study,
56
57 treatment and disease variables did not correlate with postoperative fatigue at five-month
58
59 follow-up. These findings are inconsistent with other reports in which correlations have been
60

1
2
3 found between fatigue and chemotherapy,[9] and radiotherapy.[11] However, our findings are
4
5 consistent with those from a general cancer population on the symptom cluster of pain,
6
7 fatigue, sleep disturbance, and depression. That group found that symptom experiences were
8
9 independent of demographic, disease, or treatment effects; their findings suggest that different
10
11 subgroups of patients may harbor different determinants (e.g., genetic) for experiencing
12
13 symptoms and suggested etiology that are independent of demographic, disease, or treatment
14
15 characteristics.[44]
16
17

18 19 20 *4.3. Limitations*

21
22
23 Some study limitations need to be acknowledged. There was a five-month gap between
24
25 the two measurement points. During this time, other factors might have influenced patients'
26
27 fatigue experience. Surgery type might also be a predictor of patient fatigue.[21] In this study,
28
29 only 6% of patients had video-assisted thoracoscopy; thus, it is not possible to determine
30
31 whether this influenced postoperative fatigue. Detailed information on symptom management
32
33 interventions such as physiotherapy and rehabilitation was not collected. However, even if
34
35 these variables had been included, no detailed information about the type and length of these
36
37 therapies was available.
38
39
40
41

42 43 **5. Conclusions**

44
45 Based on the findings in the present study, patients should be screened for symptoms
46
47 before surgery and offered treatment for their symptoms to reduce pre- and postoperative
48
49 fatigue. Special attention should be given to treating patients' shortness of breath, since this is
50
51 a modifiable predictor for which treatments are available. Further research should pay specific
52
53 attention to the pair of symptoms of shortness of breath and fatigue, and to the effects on
54
55 fatigue and QOL when shortness of breath is treated.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Fig. 1. Flowchart of the enrollment and exclusion of patients in the study.

For peer review only

Acknowledgements

We thank all of the patients who kindly participated and the nurses and physicians at Oslo University Hospital, St. Olav University Hospital, and Haukeland University Hospital who facilitated data collection.

Footnotes

Contributors: TR and TO conceptualised the study. TO wrote the protocol manuscript and TR contributed to protocol development. TO had responsibility for data collection. TH and AL conducted the data analyses and drafted the initial report. TO and TR critically reviewed and edited the manuscript. All authors read and approved the final manuscript. Each author contributed to interpreting the analyses and to critically revising the article, and approved the final draft.

Funding: The study was funded by the Norwegian Cancer Association.

Patient consent: Each participant signed informed consent.

Ethics approval The Regional Ethics Committee for the South-East 2010/1508, and the Institutional Review Boards (Personvernombudet) at each hospital approved the study. Each participant received written information about the study and signed informed consent.

Data availability statement: All data relevant to the study are included in the article.

Competing interests: None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

References

1 Kreftregisteret. Available from <https://www.kreftregisteret.no/en/General/Publications/Cancer-in-Norway/cancer-in-norway-2017/> (Accessed 10 May 2019).

1
2
3 2 Cheville AL, Novotny PJ, Sloan JA et al. Fatigue, dyspnea, and cough comprise a
4 persistent symptom cluster up to five years after diagnosis with lung cancer. *J Pain Symptom*
5 *Manage* 2011;42:202–212. doi:10.1016/j.jpainsymman.2010.10.257.

6
7 3 Hung R, Krebs P, Coups EJ, et al. Fatigue and functional impairment in early-stage non-
8 small cell lung cancer survivors. *J Pain Symptom Manage* 2011;41:426–435.
9 doi:10.1016/j.jpainsymman.2010.05.017.

10
11 4 Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and
12 Management. *Oncologist* 1991;4:1–10. doi:10.1097/01893697-200119020-00038.

13
14 5 Lee KA, Hicks G, Nino-Murcia G, Validity and reliability of a scale to assess fatigue.
15 *Psychiatry Res* 1990;36:291–298. doi:10.1016/0165-1781(91)90027.

16
17 6 Carnio S, Di Stefano RF, Novello S. Fatigue in lung cancer patients: symptom burden
18 and management of challenges. *Lung Cancer (Auct)* 2016;7:73–82. doi:
19 10.2147/LCTT.S85334 [Published Online First:9 May 2016]

20
21 7 Sarna L, Padilla G, Holmes C, et al. Quality of life of long-term survivors of non-small-cell
22 lung cancer. *J. Clin Oncol* 2002;20:2920–2929. doi:10.1200/JCO.2002.09.045.

23
24 8 Cheville AL, Novotny PJ, Sloan JA, et al. The value of a symptom cluster of fatigue,
25 dyspnea, and cough in predicting clinical outcomes in lung cancer survivors. *J Pain Symptom*
26 *Manag* 2011;42:213–221. doi:10.1016/j.jpainsymman.2010.11.005.

27
28 9 Long NH, Thanasilp S, Thato R. A causal model for fatigue in lung cancer patients
29 receiving chemotherapy. *Eur J Oncol Nurs* 2016;21:242-247.
30 doi:10.1016/j.ejon.2015.10.010.

31
32 10 Molassiotis A, Lowe M, Blackhall F, et al. A qualitative exploration of a respiratory distress
33 symptom cluster in lung cancer: cough, breathlessness and fatigue. *Lung Cancer*
34 2011;71:94–102. doi:10.1016/j.lungcan.2010.04.002.

35
36 11 Ozturk A, Sarihan S, Ercan I, et al. Evaluating quality of life and pulmonary function of
37 long-term survivors of non-small cell lung cancer treated with radical or postoperative
38 radiotherapy. *Am J Clin Oncol* 2009;32:65-72. doi:10.1097/COC.0b013e31817e6ec2.

39
40 12 Sarna L, Cooley ME, Brown JK, et al. Symptom severity 1 to 4 months after thoracotomy
41 for lung cancer. *Am J of Crit Care* 2008;17:455-467.

42
43 13 Poghosyan H, Sheldon LK, Leveille SG, et al. Health-related quality of life after surgical
44 treatment in patients with non-small cell lung cancer: a systematic review. *Lung Cancer*
45 2013;81:11-26. doi:10.1016/j.lungcan.2013.03.013.


46
47 14 Hoffman AJ, Given BA, von Eye A, et al. Relationships among pain, fatigue, insomnia,
48 and gender in persons with lung cancer. *Oncol Nurs Forum* 2007;34:785.
49 <http://ezproxy.diastud.no/docview/223105953?accountid=37793>.

50
51 15 Wright F, Melkus GDE, Hammer M, et al. Trajectories of evening fatigue in oncology
52 outpatients receiving chemotherapy. *J Pain Symptom Manag* 2015;50:163-175.
53 doi:10.1016/j.jpainsymman.2015.02.015.

54
55 16 Wright F, Melkus GDE, Hammer M, et al. Predictors and trajectories of morning fatigue
56 are distinct from evening fatigue. *J Pain Symptom Manag* 2015;50:176-189.
57 doi:10.1016/j.jpainsymman.2015.02.016

- 1
2
3
4 17 Storey DJ, Waters RA, Hibberd CJ, et al. Clinically relevant fatigue in cancer outpatients:
5 the Edinburgh Cancer Centre symptom study. *Ann Oncol* 2007;18:1861-1869.
6 doi:10.1093/annonc/mdm349. [Published Online First: 5 September 2007]
7
- 8 18 Huang X, Zhou W, Zhang Y. Features of fatigue inpatients with early-stage non-small
9 cell lung cancer. *J Res Med Sci*; 2015;20:268–272.
10
- 11 19 Lerdal A, Wahl A, Rustøen T, Hanestad BR, Moum T. Fatigue in the general population: a
12 translation and test of the psychometric properties of the Norwegian version of the fatigue
13 severity scale. *Scand J Public Health* 2005;33:123-130. doi:10.1080/14034940410028406
14
- 15 20 Loge JH, Ekeberg Ø, Kaasa S. Fatigue in the general Norwegian population: Normative
16 data and associations. *J Psychosomatic Research* 1998;45:53-65. doi:10.1016/S0022-
17 3999(97)00291-2
18
- 19 21 Yang P, Chevillat AL, J.A. Wampfler JA, et al., Quality of life and symptom burden among
20 long term lung cancer survivors: changing and adapting, *J Thorac Oncol* 2012;7:64–70.
21 [doi:10.1097/JTO.0b013e3182397b3e](https://doi.org/10.1097/JTO.0b013e3182397b3e).
22
- 23 22 Oksholm T, Rustoen T, Cooper B, et al. Trajectories of symptom occurrence and severity
24 from before through five months after lung cancer surgery. *J Pain Symptom Manag*
25 *2015;49:995–1015*. doi:10.1016/j.jpainsymman.2014.11.297.
26
- 27 23 Oksholm T, Miaskowski C, Solberg S, et al., Changes in symptom occurrence and
28 severity before and after lung cancer surgery, *Cancer Nurs* 2015;38:351–357. doi:
29 10.1097/NCC.000000000000198. [Published Online First: 7 July 2014]
30
- 31 24 Oksholm T, Miaskowski C, J.S. Kongerud JS, et al. Does age influence the symptom
32 experience of lung cancer patients prior to surgery? *Lung Cancer* 2013;82:156–161.
33 doi:10.1016/j.lungcan.2013.06.016.
34
- 35 25 Sangha O, Stucki G, Liang MH, et al. The Self-Administered Comorbidity Questionnaire: a
36 new method to assess comorbidity for clinical and health services research. *Arthrit Care Res*
37 *2003;49:156–163*. [doi:10.1002/art.10993](https://doi.org/10.1002/art.10993).
38
- 39 26 Miaskowski C, Lee KA. Pain, fatigue, and sleep disturbances in oncology outpatients
40 receiving radiation therapy for bone metastasis: a pilot study. *J Pain Symptom Manag*
41 *1999;17:320–332*. doi:10.1016/S0885-3924(99)00008-1.
42
- 43 27 Lerdal A, Kottorp A, Gay CL, et al. Lee Fatigue and Energy Scales: exploring
44 aspects of validity in a sample of women with HIV using an application of a Rasch model,
45 *Psychiatry Res* 2013;205;241–246. [doi:10.1016/j.psychres.2012.08.031](https://doi.org/10.1016/j.psychres.2012.08.031).
46
- 47 28 Bergman B, Aaronson N, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular
48 supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in
49 lung cancer clinical trials. *Eur J Cancer* 1994;30:635–642. [doi:10.1016/0959](https://doi.org/10.1016/0959-8049(94)90535-5)
50 8049(94)90535-5.
51
- 52 29 Giesinger JM, Kieffer JM, Fayers PM, et al. Replication and validation of higher order
53 models demonstrated that a summary score for the EORTC QLQ-C30 is robust. *J Clin*
54 *Epidemiol* 2016;69:79–88. doi:10.1016/j.jclinepi.2015.08.007.
55
- 56 30 Michelson H, Bolund C, Nilsson B, et al. Health-related quality of life
57 measured by the EORTC QLQ-C30: reference values from a large sample of the Swedish
58
59
60

- 1
2
3 population. *Acta Oncol* 2000;39:477–484. doi:10.1080/028418600750013384
4
5 31 Radloff LS. The CES-D scale: a self-report depression scale for the general population,
6 *Appl Psych Mea*. 1977;1:385–401. doi:10.1177/014662167700100306.
7
8 32 Sheehan JT, Fifield J, Reisine S, et al. The measurement structure of the Center
9 for Epidemiologic Studies Depression Scale. *J Pers Assess* 1995;64:507-521.
10 doi:10.1207/s15327752jpa6403_9.
11
12 33 Spielberger CD, Gorsuch RC, Lushene RE, et al. Manual for the
13 State-Trait Anxiety Inventory (Form Y): Self-Evaluation Questionnaire. Consulting
14 Psychologists Press, Palo Alto, CA, 1983.
15
16 34 Cataldo JK, Brodsky JL. Lung cancer stigma, anxiety, depression and symptom
17 Severity. *Oncology* 2013;85:33–40. doi:10.1159/000350834.
18
19 35 Lee KA. Self-reported sleep disturbances in employed women. *Sleep* 1992;15:493-
20 498. doi:10.1093/sleep/15.6.493.
21
22 36 Cleeland CS, Measurement and prevalence of pain in cancer. *Seminars in Onc Nurs*
23 1985;1:87–92. doi: 10.1016/S0749-2081(85)80041-3.
24
25 37 Klepstad P, Loge JH, Borchgrevink PC, et al. The Norwegian Brief Pain Inventory
26 Questionnaire: translation and validation in cancer pain patients. *J Pain Symptom Manag*
27 2002;24: 517–525. doi /10.1016/S0885-3924(02)00526-2.
28
29 38 von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational
30 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
31 *BMJ* 2007;335:806-8.
32
33 39 Cohen J. A power primer: quantitative methods in psychology. *Psychological Bulletin*
34 1992;112;155-159. doi:10.1037/0033-2909.112.1.155
35
36 40 Soper DS. Post-hoc statistical power calculator for hierarchical multiple regression
37 (Software) 2017. Available from: <http://www.danielsoper.com/statcalc/references.aspx?id=17>
38 (Accessed 10 May 2019).
39
40 41 Esper P, Heidrich D. Symptom clusters in advanced illness. *Seminars in Oncology*
41 *Nursing* 2005;25:20–28. doi:10.1053/j.soncn.2004.10.004.
42
43 42 Lin S, Chen Y, Yang L, et al. Pain, fatigue, disturbed sleep and distress comprised a
44 symptom cluster that related to quality of life and functional status of lung cancer surgery
45 patients. *J Clinical Nurs* 2013; 22.9-10:1281–1289. doi:10.1111/jocn.12228. [Published
46 Online First: 10 April 2013]
47
48 43 Yun YH, Kim YA, Min YH, et al., Health-related quality of life in disease-free survivors of
49 surgically treated lung cancer compared with the general population, *Ann Surg*
50 2012;255:1000–1007. doi:10.1097/SLA.0b013e31824f1e9e.
51
52 44 Miaskowski C, Cooper BA, Paul SM, et al. Subgroups of patients with cancer with
53 different symptom experiences and quality-of-life outcomes: a cluster analysis. *Oncol Nurs*
54 *Forum* 2006;33.
55
56
57
58
59
60



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Page: 1 and 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page: 2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page: 3 and 4
Objectives	3	State specific objectives, including any prespecified hypotheses Page: 4
Methods		
Study design	4	Present key elements of study design early in the paper Page: 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page: 5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Page: 5 and 6
		(b) For matched studies, give matching criteria and number of exposed and unexposed Page: Not actual
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page: 5-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page: 5-8
Bias	9	Describe any efforts to address potential sources of bias Page: Not actual
Study size	10	Explain how the study size was arrived at Page: 10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page:
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page: 9
		(b) Describe any methods used to examine subgroups and interactions Page: 9
		(c) Explain how missing data were addressed Page: 9
		(d) If applicable, explain how loss to follow-up was addressed Page: 9
		(e) Describe any sensitivity analyses Page: 9

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page: Fig 1, page 10
		(b) Give reasons for non-participation at each stage Page: Fig 1, page 10
		(c) Consider use of a flow diagram Page: Fig 1, page 10
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page: 11
		(b) Indicate number of participants with missing data for each variable of interest Page: 11
		(c) Summarise follow-up time (eg, average and total amount) Page: 11
Outcome data	15*	Report numbers of outcome events or summary measures over time Page: 10 -12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Page: 12
		(b) Report category boundaries when continuous variables were categorized Page: 12
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Page: Not actual
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Page: Not actual
Discussion		
Key results	18	Summarise key results with reference to study objectives Page: 14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page: 2 + 16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page: 15 and 16
Generalisability	21	Discuss the generalisability (external validity) of the study results Page: 16
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page: 18

*Give information separately for exposed and unexposed groups.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

For peer review only